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Recent studies have demonstrated the efficacy of hematopoietic cell-based
therapies in promoting therapeutic angiogenesis for a wide variety of vascular
syndromes, however the cell populations responsible and the mechanisms involved
are poorly understood. Using a mouse model of hindlimb ischemia, we previously
showed that an adoptive transfer of donor monocytes significantly enhanced
revascularization. Monocytes are a widely heterogeneous cell population and
differences in the ability of various monocyte subsets to mediate revascularization
have not been previously investigated. Using the hindlimb ischemia model we
demonstrate that an adoptive transfer of inflammatory (CX3CR loGr-1+), but not
resident (CX3CR1hiGr-1-) monocytes, significantly enhances revascularization postischemia. Additionally, we show that the inflammatory subset of monocytes is
selectively recruited from the bone marrow to the blood and that these cells
accumulate at the ischemic lesion. These findings demonstrate that the adoptive
transfer of only a small proportion of monocytes from a non-ischemic donor
significantly enhances revascularization despite the presence of a far greater

ii

proportion of endogenous (ischemia-conditioned) monocytes. Herein, we provide
data suggesting that upon induction of distant ischemia, systemic signals are
generated which reduce the angiogenic capacity of bone marrow resident monocytes.
We provide evidence that granulocyte-colony stimulating factor (G-CSF) and
interleukin-6 (IL-6) provide these “conditioning” signals. Systemic levels of G-CSF
and IL-6 are significantly increased following induction of hindlimb ischemia, and
accordingly, bone marrow resident monocytes from ischemic mice exhibited
increased STAT3 phosphorylation and STAT3 target gene expression. Finally, GCSF receptor-/- and IL-6-/- mice were resistant to the deleterious effects of ischemic
conditioning on monocyte angiogenic potential. The mechanism by which this
ischemia-driven signals limit the angiogenic potential of monocytes was examined
using RNA expression profiling which suggested that ischemia-conditioned
monocytes in the bone marrow are polarized towards expression of M2-associated
genes. Consistent with this observation, M2-skewed monocytes from SHIP-/- mice
also had impaired angiogenic capacity. Lastly we demonstrate that the efficacy of an
adoptive transfer of non-ischemic donor monocytes may be due, at least in part, to
increased expression of the fractalkine receptor CX3CR1 as well as to increases in
local concentrations of the angiogenic factors MCP-1, VEGF, MMP-9 and ApoA1.
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Chapter 1

Introduction

1

1.1 Angiogenesis
1.1.1 Types of neovascularization
Neovascularization is a critical biological process in a variety of
developmental, repair, and pathological settings. The general term neovascularization
describes three distinct processes that result in the formation of blood vessels:
vasculogenesis, arteriogenesis, and angiogenesis. Vascuolgenesis refers to the de
novo formation of vascular structures from mesenchymal angioblasts (Risau, 1995).
Postnatally, some vasculogenesis mediated by endothelial progenitor cells may occur,
however the contribution of this process to adult neovascularization is controversial
(Asahara, 1999; Simons, 2003). In adults, blood vessel formation occurs by two
distinct mechanisms referred to as angiogenesis and arteriogenesis. Arteriogenesis
refers to the enlargement of pre-existing vessels to form arteries which have 3 distinct
wall layers as well as vasomotor activity (Helisch, 2003). In contrast, during
angiogenesis new capillary networks are formed due to the recruitment of local
endothelial cells from nearby vessels which assemble into vascular structures in a
process referred to as tube formation (Folkman, 2005). The two processes by which
angiogenesis can occur are referred to as “sprouting” in which a new branch is
formed from an existing vessel, or “intussusception” which refers to the splitting of a
pre-existing capillary. Each of these processes results in the formation of a thinwalled endothelial cell-lined capillary. The studies outlined below will focus
exclusively on post-ischemic neovascularization. Angiogenesis is a major contributor
to post-ischemic neovascularization as only this process, and not arteriogenesis, is
induced in response to hypoxia-inducible factor-1α (HIF-1α) expression which is
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induced under conditions of ischemia/hypoxia (Madeddu, 2005; Schaper, 2003).
However, both angiogenic and arteriogenic mechanisms are triggered by shear stress
which is generated in ischemic tissues and thus both processes are involved in
recovery from ischemic insult.

1.1.2 Hindlimb ischemia model of angiogenesis
In order to study post-ischemic neovascularization, we will utilize a mouse
model first described by Couffinhal, et al. for femoral artery excision (FAE) which
results in hindlimb ischemia (HLI) (1998). In this model, the right hindlimb is
dissected to allow visualization of the femoral artery. The obturator nerve which runs
directly parallel and in close proximity to the femoral artery is dissected away from
the artery taking care that it remains intact. The femoral artery and all of its side
branches, as well as the proximal saphenous artery are then ligated and the portions of
the vessels located between these points of ligation are excised. Laser Doppler
imaging is used to monitor the disruption and subsequent restoration of blood flow to
the ischemic hindlimb. Imaging software assigns a “flux value” describing the
surface blood flow observed. As ischemia is induced in a unilateral fashion, the
amount of blood flow present in the non-ischemic leg is used as an internal control to
minimize variations among individual mice. Blood flow recovery is thus reported as
the ratio of the flux value observed in ischemic hindlimb divided by the flux value
observed in the non-ischemic hindlimb abbreviated as (ischemic:non-ischemic). Prior
to femoral artery excision, the flux values obtained for the right and left hindlimbs are
nearly identical, resulting in a flux ratio of approximately 1.0. In contrast, post-HLI,
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blood flow to limb undergoing femoral artery excision is nearly absent, resulting in a
flux ratio of approximately 0.1. Mice are monitored over a 14-day time course to
assess revascularization. Of note, in our studies laser Doppler quantitation is
performed only on the foot region of the mouse, excluding the adductor and calf
muscle regions. Histological analyses suggest that angiogenesis is the major repair
mechanism present in the ischemic calf muscle and foot while arteriogenesis is
responsible for repair of the ischemic adductor muscle (Wahlberg, 2006; Shireman,
2007). Thus angiogenesis, and not arteriogenesis, is the major neovascularization
process reflected in this model.

Figure 1.1
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1.2 Monocyte regulation of angiogenesis
1.2.1 In vitro and animal model findings
Monocytes are known to play a critical role in promoting angiogenesis in a
wide variety of settings including wound repair, rheumatoid arthritis, tumor
development, and ischemic injury (Sunderkotter, 1994). Monocytes play a variety of
distinct roles in regulating the angiogenic process. First, they exhibit proteolytic and
phagocytic activity which allows for the degradation and removal of damaged tissue,
thus generating an appropriate scaffolding upon which new blood vessels can be
formed. Secondly, macrophages generate a wide range of cytokines which recruit
and/or activate additional inflammatory cells (MCP-1, IL-8) or endothelial cells
(VEGF). Lastly, several studies have reported that monocytes may, in fact, be able to
incorporate into developing vasculature. Recent evidence however, has demonstrated
that CD45+ hematopoietic cells do not incorporate into developing endothelium
(Capoccia, 2006). Monocytes are recruited to hypoxic areas and produce angiogenic
factors which stimulate endothelial cells located in nearby areas to migrate,
proliferate, and differentiate into new vessels (Lewis, 2005). In response to hypoxia,
macrophages produce VEGF, a mitogen specific to endothelial cells which is potently
angiogenic (Leung, 1989). Additionally, macrophages have been shown to express
the inflammatory mediators IL-1, TNF, IL-6, and arginase-1 (Arg1) in response to
hypoxia (Bosco, 2008).
In addition to the phagocytic, proteolytic, and proinflammatory properties
described above, monocyte/macrophages have also been ascribed two unique
functions outlined in recent studies. First, although macrophages are largely thought
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to be non-dividing, several studies have indicated a limited degree of proliferation in
response to co-culture with endothelial cells and M-CSF in vitro (Cheung, 1992;
Munn, 1993; Antonov, 1997). However, the contribution of local proliferation of
macrophages under inflammatory conditions in vivo is unclear. Second, an additional
study using a mouse transgenic model of ischemic cardiomyopathy has indicated that
macrophages can drill endothelial cell-free“tunnels” using macrophage
metalloelastase which penetrate the ischemic myocardium (Moldovan, 2000).
Whether of not these tunnels are subsequently colonized by endothelial cells to form
capillaries is unknown.
In light of the well-established important roles played by monocytes in
mediating angiogenesis, several groups have explored the possibility that a local
injection or intravenous adoptive transfer of monocytes may serve as an efficacious
treatment for a variety of angiogenic disorders. Recent studies by Capoccia et al.
have demonstrated that an adoptive transfer of bone marrow mononuclear cells, and
in particular the monocyte fraction contained within this population, significantly
enhanced blood flow recovery post-hindlimb ischemia in mice (2006, 2008). These
findings were corroborated by (Zhang, 2008) and extended to myocardial infarction
models (Burchfield, 2008; Ziebart, 2008). Studies such as these provided the
rationale for the clinical trials described below.
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1.2.2 Clinical trials utilizing monocytes
Promising reports using mouse modeling have prompted a variety of clinical
trials in which bone marrow-derived mononuclear cells are used as a treatment for
ischemic disorders including myocardial infarction and critical limb ischemia.
Critical limb ischemia (CLI) is a severe manifestation of peripheral arterial disease
(PAD). The estimated annual incidence of CLI ranges between 500 and 1,000 new
cases per 1 million, and occurs most frequently in patients with diabetes or severe
atherosclerosis (Minar, 2009). The primary goals of treatment in patients with CLI
are to relieve ischemic pain and to treat ischemic ulcers, and in the most severe cases
to prevent loss of the ischemic limb. In an effort to treat CLI, the growth factor
proteins VEGF and bFGF have been administered locally, however results to this
type of treatment have been mixed (Al Sabti, 2007). These mixed results are not
entirely surprising as these proteins have a short serum half-life and a sole factor is
unlikely to recapitulate all the signals necessary to induce angiogenesis.
As a means of circumventing the limitations of single protein therapies, recent
studies have focused on cell-based approaches to therapeutic angiogenesis. Studies in
animal models demonstrating the efficacy of hematopoietic cells, in promoting
angiogenesis led to the rapid development of clinical trials in which autologous
hematopoietic cells were injected intramuscularly into the ischemic limb. These
studies utilize autologous bone marrow mononuclear cells (BM-MNCs) obtained
directly from bone marrow aspirates or G-CSF-mobilized peripheral bloodmononuclear cells (PB-MNCs).

In one group of trials, summarized in Table 1,

autologous BM-MNCs were injected intramuscularly into the ischemic limb of
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patients with critical limb ischemia. In each of these trials therapeutic benefits were
observed in the treatment group as measured by a variety of indicators including
improvements in ankle-brachial index, mean walking distance, and collateral
formation. While these promising findings have been reported for critical limb
ischemia, similar myocardial infarction trials have yielded disappointing results.
Little efficacy has been observed using either BM-MNC or PB-MNC therapies
(Dimmeler, 2008). Therefore an understanding of the specific pro-angiogenic
populations contained within the mononuclear cell compartment and the mechanism
by which these cells promote angiogenesis may reveal important information about
how to improve the design of these therapies for myocardial infarction patients.

1.3 Monocyte biology
1.3.1 Development and functions
Monocytes are mononuclear cells that develop from a common myeloid
progenitor in the bone marrow and are released into the blood under both basal and
pathogenic conditions (Fogg, 2006). Monocytes comprise approximately 5-10% of
the total leukocyte population in the blood where they exhibit a relatively brief
lifespan. Monocytes in mice and humans demonstrate a half-life of 17 hours (van
Furth, 1989) and 71 hours (Whitelaw, 1972), respectively. Upon recruitment to
peripheral tissues, monocytes can follow one of two differentiation pathways
generating either macrophages or dendritic cells (DCs). Macrophages engulf dead
cells and debris, proteolytically degrade this cellular material, and release cytokines
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which further promote the clearance of dead cells. After processing this cellular
debris, macrophages do not process or present antigens or generate a T cell response
(Zammit, 2005). DCs likewise phagocytose cellular debris but in addition they
process and present them to T cells via MHC molecules (Trombetta, 2003). The
migration properties of these cell types likewise differ: while macrophages remain
largely confined to tissues, DCs can traffick from the tissues to peripheral lymphoid
organs. In addition to deriving from bone marrow/blood precursors, some
macrophage populations, such as the pulmonary macrophages are known to selfrenew from local precursors (Tarling, 1987). After emigrating from the blood to
tissues, macrophages can exhibit any of a wide array of phenotypes depending on
local signals as outlined below.

1.3.2 M1/M2 polarization
In response to a variety of stimuli, monocytes are recruited from the bone
marrow to the blood and subsequently to peripheral tissues where they can
differentiate into several effector macrophage subsets. Infectious and proinflammatory stimuli generate signals which drive macrophages down the classical
activation or M1 pathway. In vitro, cells exhibiting an M1 phenotype can be
generated by treating with interferon-γ (IFN-γ) or lipopolysaccharide (LPS). M1
polarized macrophages produce a panoply of inflammatory mediators and utilize the
nitric oxide synthase pathway to generate large amounts of nitric oxide (NO).
Accordingly, nitric oxide measurements are frequently used as an assessment of
polarization to the M1 phenotype (Mills, 2000). Conversely, macrophages can
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undergo alternative activation to polarize along the M2 pathway. Alternative
activation occurs biologically upon infection with parasitic helminths or in response
to allergens. This subset of macrophages is referred to at M2a. In addition, M2
polarization can occur in response to activation by immune complexes, generating a
subset called M2b. Lastly, the M2 phenotype can be generated in response to IL-10
production at the resolution of inflammation (Kreider, 2007). In keeping with in vivo
observations, polarization towards the M2 phenotype can be driven in vitro by
treating with IL-4, IL-13, or IL-10. M2 polarized macrophages utilize the arginase
pathway and expression of arginase 1 (Arg1) is a distinct marker for this cell type.
Additionally, expression of the markers Ym1/chitinase and FIZZ1 are widely
accepted as M2 markers across all M2 subsets and are upregulated in response to the
vast majority of helminth infections (Martinez, 2009).
Genetic mouse models for M1 or M2 polarization have been described, but
are wrought with important caveats. Mice lacking Src homology inositol phosphotase
(SHIP) demonstrate a skewing towards increased M2 polarization as SHIP has been
found to repress alternative activation in macrophages in vitro (Rauh, 2005). In
addition, PPAR-gamma deficiency has been shown to result in preferential M1
macrophage polarization (Odegaard, 2007). Interestingly, these phenotypes are
highly dependent upon mouse strain. For example, in the Th1-permissive Balb/c
mouse strain, PPAR-gamma deficiency results in increased M1 polarization, however
in the Th1-resistant C57Bl/6 mouse strain this phenotype is not observed.
While M1-polarized macrophages clearly play a role in inflammatory
processes, the role of M2-polarized macrophages is less clear. M2a macrophages in
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concert with Th2 cells to elicit antibody-mediated immunity which allows antibodies
to coat invading parasites such that they can be cleared via a process referred to as
antibody-dependent cell-mediated cytotoxicity (ADCC). Monocytes exhibiting an
M2 phenotype have been extensively reported in a variety of tumor models (Nardin,
2008).
The ability of M1 or M2 macrophage subsets to influence angiogenesis
outside of the tumor microenvironment has not been extensively studied, however
one report indicates that IL-4-inducted M2 macrophages elicited a 3-fold greater
proliferation in endothelial cells in vitro compared to IFN-g-elicited M1 macrophages
(Kodelja, 1997). The studies described in Chapter 3 will assess M1 and M2
polarization phenotypes in an ischemic setting.

1.3.3 CX3CR1 monocyte subsets
Monocytes are a widely heterogeneous cell population in which the full extent
of existing subsets and the plasticity between subsets is largely unknown. One major
subset designation in monocytes has been recently described based upon differential
expression of the cell surface markers CX3CR1 and Gr-1 (Table 2). In the bone
marrow, monocytes can be divided into two distinct populations based upon these
markers, namely CX3CR1hiGr-1- and CX3CR1loGr-1+ subsets. The CX3CR1loGr-1+
subset is referred to as the inflammatory subset, due to the ability of these cells to
migrate to the peritoneum in response to intraperitoneal thioglycollate. In addition,
these cells express the adhesion markers VCAM-1 and L-selectin, as well as the
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chemokine receptor CCR2. In contrast, cells of the CX3CR1hiGr-1- subset do not
traffic to the peritoneum in response to thioglycollate treatment and do not express
the adhesion markers or chemokine receptors observed in the inflammatory subset
(Geissmann, 2008). Based on these observations, this subset is referred to as the
resident subset. While the precise function of this subset is unclear, a recent study
has suggested that the resident monocyte subset patrols blood vessels, allowing rapid
tissue invasion and subsequently give rise to macrophages while inflammatory
monocytes reach the inflammatory site at a later time and differentiate into
inflammatory DCs (Auffray, 2007). Subsets analogous to the mouse inflammatory
and resident subsets have been described in humans in which a CD14hiCD16population resembles the inflammatory monocyte population while CD14+CD16+ is
functionally comparable to the resident subset (Table 3) (Zeigler, 2007).
The bone marrow is made up largely of the CX3CR1loGr-1+ inflammatory
subset while the resident subset dominates in the peripheral blood. Several studies
have indicated that the inflammatory population in the bone marrow may convert into
the resident population in the peripheral blood based upon labeling and tracking
studies (Tacke, 2006; Arnold, 2007).

Another study utilizing a mouse model of

myocardial infarction has indicated that the inflammatory subset is selectively
recruited first and that these cells exhibit phagocytic and proinflammatory functions
and that subsequently the healing myocardium recruits monocytes of the resident
subset which mediate angiogenesis and the deposition of collagen (Nahrendorf,
2007). While no studies have directly examined the contribution of the inflammatory
and resident subsets to angigogenesis, in the ApoE-/- atherosclerosis-prone mouse
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model, a skewing towards the CX3CR1loGr-1+ inflammatory monocyte subset was
observed in the blood and these cells also preferentially accumulated in the
atherosclerotic lesion (Tacke, 2007). Further studies are required to determine if this
subset is responsive to specifically responsive to ischemic signals or if the
accumulation of the cells is in response to inflammatory signals.

1.3.4 Tie2 monocyte subset
Recent studies have revealed a potently angiogenic monocyte subset that
expresses the receptor tyrosine kinase Tie2. The Tie2 receptor binds two major
ligands: the agonist ligand angiopoietin-1 (Ang1) and the antagonist ligand
angiopoietin-2 (Ang2). Binding of Ang1 to Tie2 receptor strengthens interactions
13

between endothelial cells and extracellular matrix (Thurston, 2000). Ang2 competes
for binding with Tie2 preventing the binding of Ang1, thus leading to destabilization
of vessels (Maisonpierre, 1997). However, in vitro, Ang-2 stimulates endothelial
cells migration and tube cell formation (Teichert-Kuliszewska, 2001). Roughly 2-5%
percent of bone marrow cells have been shown to express Tie2. Flow cytometic
analysis revealed that these Tie2+ cells present in the bone marrow were comprised of
both endothelial cells (<5% CD31+CD45−) and hematopoietic cells (>95% CD45+).
Tie2-expressing CD45+ hematopoietic cells were found to be enriched for Sca-1+ (
30%) and c-kit+ ( 50%) progenitors (De Palma, 2003). In the peripheral blood,
Tie2-expressing monocytes (TEMs) have been shown to comprise 2-7% of the total
circulating monocytes in healthy human subjects (Venneri, 2007) as well as in mice
(Lewis, 2007). TEMs in the peripheral blood largely did not express the HSC/HPC
markers c-kit (95% c-kit−) and Sca-1 (>70% Sca-1−). Interestingly, circulating TEMs
were found to exhibit a CCR2–, L-selectin-, CCR5+ phenotype—a surface profile
previously associated with resident monocytes (Gordon, 2005).
While TEMs comprise only a small fraction of blood monocytes, they are
have been found to be enriched in a variety of tumor environments. 55% and 70% of
the CD14+ monocytes present in both a colorectal and lung carcimona expressed
Tie2. It is thought that these TEMs play an important role in vascularizing tumors
based on several lines of evidence. For example, U87 tumor cells coinjected with
human CD14+Tie2+ monocytes led to larger and more highly vascularized tumors
than those observed in mice receiving U87 cells alone (De Palma, 2009). In addition,
in a knockout mouse model lacking TEMs, there was a complete prevention of human
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glioma neovascularization in the mouse brain as well as substantial tumor regression
(De Palma, 2005). It is currently unknown whether TEMs represent a unique
monocyte lineage or if this phenotype is induced by the tumor microenvironment.

1.4 CX3CR1/fractalkine receptor
Fractalkine or CX3CL1 is CX3C motif chemokine which is produced by
macrophages, activated vascular endothelial cells, smooth muscle cells, epithelial
cells, dendritic cells, and neurons (Landsman, 2009). CX3CR1 is the sole known
receptor for fractalkine ligand and is expressed on blood monocytes, T cells, DC
subsets, and natural killer (NK) cell subsets. Fractalkine ligand is a transmembrane
mucin-like stalk which mediates integrin independent adhesion to leukocytes
expressing CX3CR1 (Bazan, 1997). CX3CL1 can also be cleaved and secreted, and
in its secreted form it acts as a chemoattractant for cells bearing its cognate receptor
(Garton, 2001; Hundhausen, 2003).
Expression of fractalkine is induced in inflammatory conditions downstream
of TNF-α and IL-1 production (Bazan, 1997). IFN-g has been shown to increase
fractalkine expression in epithelial cells and dermal fibroblasts (Fujimoto, 2001;
Fahy, 2003) acting through the STAT1 signaling pathway (Lombardi, 2008). A
recent study has demonstrated that in the absence of either CX3CR1 or CX3CL1
there is a reduction in circulating monocyte levels at steady state as well as in the
inflammatory setting present in ApoE-/- atherosclerosis-prone mice (Landsman,
2009). This study also reported that overexpression of the cell survival factor Bcl2 in
CX3CR1-/- or CX3CL1-/- mice restored monocyte recruitment, suggesting that the
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CX3CR1 pathway promotes cell survival. In a model for wound healing, CX3CR1
was found to play a critical role as CX3CR1-/- mice exhibited defects in macrophage
infiltration, VEGF production, collagen deposition, and neovascularization (Ishida,
2008).
A variety of studies have indicated that fractalkine and its receptor may be
induced in response to hypoxia and may play an important role in blood vessel
growth. Specifically, hypoxia has been shown to inhibit the IFN-γ-induced
expression of fractalkine in HUVEC; however this inhibition is reversible as the
reintroduction of oxygen increases fractalkine levels (Yamashita, 2003). The addition
of exogenous fractalkine ligand has been shown to induce new vessel formation in
vitro using the rat aortic ring and chick chorioallantoic membrane in vitro assays
(Ryu, 2008). This vessel formation was associated with upregulation of HIF-1a and
VEGF-A. The role of CX3CR1 in mediating post-ischemic angiogenesis varies
according to the models tested. In a mouse model for retinal vascular repair,
CX3CR1 signaling was shown to have no role in revascularizing injured retinal tissue
(Zhao, 2009). In contrast CX3CR1-/- mice demonstrated reduced macrophage
accumulation as well as decreased injury in models for kidney ischemia/reperfusion
(Li, 2008) and focal cerebral ischemia (Denes, 2008). Interestingly, bone marrow
transplantation experiments demonstrated that mice lacking CX3CR1 in the
hematopoietic compartment were able to promote blood vessel growth within an
implanted Matrigel/fractalkine matrix whereas mice lacking CX3CR1 in all tissues
demonstrated no blood vessel growth (Ryu, 2008). This finding suggests that
CX3CR1 signaling by endothelial cells may be a greater contributor to angiogenesis
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than signaling by this receptor on hematopoietic cells, however data from other
angiogenic models is currently lacking.
In addition to an accumulating body of evidence that fractalkine may play an
important role in angiogenesis, several studies have linked fractalkine and its receptor
to atherosclerosis susceptibility. Polymorphisms in this gene which reduce the ability
of CX3CR1 to bind to its ligand are associated with a reduced risk for atherosclerosis
in humans (Lesnik, 2003). In addition CXCL1 expression has been observed in both
macrophages and coronary artery smooth muscle cells in the vessels of
atherosclerotic but not normal patients (Wong 2003, Lucas 2002). While the role of
CX3CR1/CX3CL1 in leading to atherosclerosis is unclear a recent study has
demonstrated that the lipid components of low density lipoprotein (LDL) activate
peroxisome proliferator-activated receptor-γ (PPAR-γ) in macrophages leading to
decreased CCR2 expression (and therefore reduced CCR2-dependent migration) and
increased CX3CR1 expression leading to adhesion to the vessel wall (Barlic, 2006).
CX3CL1-/-ApoE-/- mice demonstrated no reduction in the number of circulating
monocytes, however there was a significant reduction in the number of macrophages
which infiltrated the atherosclerotic lesion (Saederup, 2007). This finding suggests a
role for CX3CL1 in the capture and retention of monocytes by the endothelium and
not in their ability to traffick from the bone marrow to the periphery. Taken together
the aforementioned studies indicate a clear role for the CX3CR1/CX3CL1 interaction
in the retention of monocytes at inflammatory and ischemic lesions.

1.5 Apolipoprotein A1
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ApoA1 is the major protein component of high density lipoprotein (HDL).
ApoA1 is synthesized in the liver and small intestine, exported and associates with
lipids extracellularly. The primary function of HDL is to promote reverse cholesterol
transport from the tissues to bile. HDL-associated ApoA1 is classically regarded as a
negative acute-phase protein, a term assigned to serum proteins whose levels are
decreased by at least 25% during acute inflammation (Gabay, 1999). In keeping with
its anti-inflammatory designation, ApoA1 has been shown to inhibit monocyte
activation in vitro (Murphy, 2008). Additionally, gene transfer of ApoA1 led to
reductions in macrophage accumulation in several mouse models of atherosclerosis
(Tangirala, 1999; Paszty, 1994). Likewise, administration of ApoA1 significantly
limited macrophage-related pathology in mouse models of kidney
ischemia/reperfusion injury (Shin, 1998), myocardial infarction (Gu, 2007), and
stroke (Paterno, 2004).
While the above studies indicate an anti-inflammatory role for ApoA1, recent
evidence suggests that the precise relationship of HDL/ApoA1 to the regulation of
inflammation may, in fact, be more complex. HDL has been shown to be both proinflammatory and anti-inflammatory depending on the model tested. On the whole it
is accepted that HDL prevents inflammation in the absence of systemic inflammation
but becomes pro-inflammatory in response to systemic inflammation or an acute
phase response (Navab, 2005; van Lenten, 1995). For example, when mice were
subjected to a viral pneumonia, HDL became pro-inflammatory and resulted in a
marked increase in IL-6 production and in macrophage trafficking to the infected
areas (van Lenten, 2002). In this same study, when mice were treated with an ApoA1
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mimetic peptide, a dramatic reduction in macrophage accumulation and IL-6
production was observed. Interestingly, increased levels of ApoA1 have been
observed in the synovial fluid of rheumatoid arthritis patients concomitant with a
reduction in serum levels of this protein (Oliviero, 2009; Ananth, 1993). It is unclear
whether the redistribution of this protein from the circulation to the inflammed joint is
a mechanism to reduce inflammation or if it is, in fact, contributing to the pathology.
With respect to vascular models, one study has demonstrated that ApoA1
stimulates endothelial cell migration in vitro (Seethram, 2006). Additionally, mice
lacking ApoA1 demonstrate impaired revascularization in response to carotid artery
injury and this defect is rescued by reconstitution of ApoA1 expression by gene
transfer (Seetharam, 2006). Another study revealed that treatment of mice with
recombinant HDL post-hindlimb ischemia significantly improves blood flow
recovery in an endothelial nitric oxide synthase (eNOS)-dependent fashion (Sumi,
2007). Based on these studies and findings described above, ApoA1 clearly plays a
role in the regulation of revascularization as well as macrophage recruitment. In
Chapter 2 we will examine the contribution of this protein to the recovery from
hindlimb ischemia.
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1.6 Summary
This study will center on defining the proangiogenic subsets of monocytes and
also exploring the mechanism by which these cells improve angiogenesis. Three
main questions will be addressed:

1. What subset of monocytes is angiogenic?
2. What factors released by monocytes accelerate angiogenesis?
3. How do signals generated by ischemia impact the phenotype of endogenous, bone
marrow resident monocytes?

In Chapter 2 we will define the subset of monocytes responsible for
angiogenesis and examine the importance of two factors with a previously
undetermined role in post-ischemic angiogenesis. In Chapter 3 we will assess
differences between non-ischemic donor and ischemia-conditioned bone marrow
monocytes. Finally, in Chapter 4 we will summarize our results, discuss the
significance of this work, and outline future studies.
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Chapter 2

The Inflammatory Subset of Monocytes Potently
Stimulates Post-Ischemic Angiogenesis

Portions of this chapter are contained in the following published article:
Capoccia, B.J., Gregory, A.D., Link, D.C. Recruitment of the Inflammatory Subset of
Monocytes to Sites of Ischemia Induces Angiogenesis in an Monocyte
Chemoattractant Protein-1 Dependent Fashion. J Leukoc Biol. 2008 Sep;84(3):760-8.
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2.1 ABSTRACT

Monocytes are a widely heterogeneous cell population which has been shown to
significantly accelerate angiogenesis in a variety of models. Differences in the ability
of various monocyte subsets to mediate revascularization have not been previously
investigated. Herein, we address the two subsets of monocytes designated based on
differential expression of CX3CR1 and Gr-1, the CX3CR loGr-1+ inflammatory subset
and the CX3CR1hiGr-1- resident subset. Using a mouse model for hindlimb ischemia,
we demonstrate that an adoptive transfer of the inflammatory subset, but not the
resident subset, significantly enhances revascularization post-ischemia. Additionally,
we show that the inflammatory subset of monocytes is selectively recruited from the
bone marrow to the blood upon induction of ischemia. Accordingly an accumulation
of monocytes of the inflammatory subset is observed at the ischemic lesion at all
analyzed timepoints post-hindlimb ischemia. Lastly we demonstrate that the efficacy
of an adoptive transfer of inflammatory monocytes may be due, at least in part, to
increased expression of the fractalkine receptor CX3CR1 as well as to increases in
local concentrations of the angiogenic factors MCP-1, VEGF, MMP-9 and ApoA1.

2.2 INTRODUCTION

Peripheral arterial disease is an atherosclerosis-associated syndrome which
affects nearly 15% of the United States population over the age of 55 (Weitz, 1996).
Critical limb ischemia is a severe manifestation of peripheral arterial disease and is a
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leading cause of limb amputation. Various strategies have been used in an effort to
restore angiogenesis in the setting of critical limb ischemia, including cytokine and
cell therapies. Treatment with growth factors alone, namely VEGF (Rajagopalan,
2003) and rFGF (Lederman, 2002) has demonstrated little efficacy in clinical trials.
Based on the assumption that treatment with a single growth factor is unlikely to
recapitulate all the signals necessary for angiogenesis, recent studies have focused on
the ability of hematopoietic cell-based therapies to mediate revascularization.
Notably, several studies have demonstrated that intramuscular injections of bone
marrow mononuclear cells (BM-MNCs) or apheresed, G-CSF-mobilized peripheral
blood-mononuclear cells (PB-MNCs) can improve revascularization as assessed by
several indicators including improvement of ischemic ulcers, increase in maximum
walking distance, and a reduction in amputations (Al Mheid, 2008). Mobilization of
the patients’ own mononuclear cells via G-CSF (Arai, 2006) or GM-CSF (van Royen,
2005) has likewise shown promise as a treatment for critical limb ischemia.
However, as a non-specific and widespread mobilization or local injection of a
heterogeneous population of inflammatory cells may have deleterious side effects,
particularly within the context of atherosclerosis, there exists a demand for cell-based
therapies in which a small population of highly angiogenic cells is targeted to the
ischemic tissue.
Recent studies by our laboratory have demonstrated that of the major cell
types contained within the mononuclear cell fraction, monocytes exhibit the most
potent angiogenic activity (Capoccia, 2006). Monocytes play a variety of roles in the
angiogenic process, including the secretion of a variety of factors including VEGF,
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bFGF, TGF-a, GM-CSF, IL-8, and PDGF. These factors promote proliferation and
migration of endothelial cells as well as tube formation (Sunderkotter, 1994).
Activation of endothelial cells by these cytokines induces production of VEGF and
MCP-1, providing a positive amplification loop leading to the recruitment of
additional monocytes (Shireman, 2007). Additionally, monocytes express
metalloproteases and serine proteases which play a critical role in degradation of the
extracellular matrix, thus generating an appropriate scaffolding upon which new
vessels can form (Moldovan, 2005). Mice subjected to ischemia exhibit a marked
endogenous monocytic response, consisting of increased production in the bone
marrow and trafficking to the lesion (Capoccia, 2008). Additionally, ablation of
macrophages is associated with a significant reduction in post-ischemic angiogenesis
(Heil, 2002; DiPietro, 1993; Brechot, 2008). Therefore a determination of the
mechanisms governing monocyte recruitment and retention at ischemic sites as well
as an understanding of what constitutes a proangiogenic phenotype may reveal
important therapeutic strategies for the treatment of ischemic disorders.
Geissmann and colleagues described two unique monocytic populations
present in the bone marrow and blood based on differential expression of the
fractalkine receptor, CX3CR1, and Gr-1 (2003). The fractalkine receptor CX3CR1
binds to fractalkine ligand (CX3CL1) and this interaction promotes adhesion. Both
CX3CR1 and its ligand are expressed on hematopoietic cells, including monocytes, as
well as endothelial cells. Cells with a CX3CR1loGr-1+ phenotype were named
“inflammatory” based on the observation that these cells traffick from the bone
marrow to the peritoneum in response to intraperitoneal injections of thioglycolate.
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In contrast, cells exhibiting the CX3CR1hiGr-1- phenotype, did not respond to
challenge with thioglycolate and were thus referred to as the “resident” subset. A
recent study has indicated that cells of the inflammatory subset may convert into
resident cells in the periphery, however the precise relationship between these subsets
is not fully defined (Tacke, 2006).
Herein, we provide evidence that the inflammatory subset of monocytes is
preferentially recruited from the bone marrow to the peripheral blood to the site of
ischemia. In accordance with this finding, an adoptive transfer inflammatory
monocytes significantly improves revascularization post-hindlimb ischemia (HLI).
This improvement is associated with an increased influx of endogenous monocytes to
the ischemic lesion as well as increased local production of the known angiogenic
factors vascular endothelial growth factor-A (VEGF-A), monocyte chemotactic
protein-1 (MCP-1), matrix metalloprotease-9 (MMP-9), as well as of apolipoprotein
A1 (ApoA1). Additionally, we show that an adoptive transfer of ApoA1-/inflammatory monocytes does not improve revascularization post-HLI, demonstrating
for the first time an important role for this protein in mediating post-ischemic
angiogenesis.
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2.3 MATERIALS AND METHODS

Mice. ApoA1-/- mice on a C57BL/6 background were obtained from The Jackson
Laboratory (Bar Harbor, ME, USA). CX3CR1GFP/+ and CX3CR1GFP/GFP mice on a
C57BL/6 background were a generous gift from Dr. Dan Littman (Skirball Institute of
Biomolecular Medicine, New York University School of Medicine, New York, NY,
USA). Mice were housed in a specific pathogen-free environment. The Washington
University Animal Studies Committee (St. Louis, MO, USA) approved all
experiments.

Murine hindlimb ischemia model. The hindlimb ischemia surgical procedure was
performed as described previously (Couffinhal, 1998). In brief, an incision was made
in the skin at the mid-portion of the right hindlimb overlying the femoral artery, and
the femoral artery and vein were then dissected free from the nerve, and the proximal
portion of the femoral artery and vein ligated with 6-0 silk sutures. The distal portion
of the saphenous artery and vein and remaining arterial and venous side branches
were ligated, followed by their complete excision from the hindlimb. The overlying
skin was then closed using Nexaband veterinary glue (Abbott Animal Health, Abbott
Park, IL, USA).

Laser Doppler perfusion imaging. Blood perfusion in the hindlimb was monitored by
laser Doppler imaging (MoorLDI-2, Moor Instruments, UK). Before initiating
scanning, mice were anesthetized with ketamine/xylazine and placed on a heating
plate at 37°C to minimize temperature variations. For each time-point, the laser
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Doppler image obtained was analyzed by averaging the perfusion, expressed as the
relative unit of flux as determined by Moor Instruments, over the surface of the
ischemic and nonischemic foot. To control for ambient light and temperature,
calculated perfusion was expressed as the flux ratio between the ischemic and
nonischemic limbs.

Inflammatory and resident monocyte subset isolation. Bone marrow mononuclear
cells from CX3CR1GFP/+ mice were incubated at 4°C with PE-conjugated Gr-1
antibody (PharMingen). CX3CR1loGr-1+ and CX3CR1hiGr-1– monocytes were
isolated using a MoFlo high-speed flow cytometer (Dako Cytomation, Fort Collins,
CO, USA).

Adoptive transfer of CFSE-labeled cells. Bone marrow was harvested from the
femurs of donor mice, and mononuclear cells were isolated by centrifugation across a
1.011 density gradient (Histopaque, Sigma-Aldrich, St. Louis, MO, USA) at 1700 x g
for 30 min. Mononuclear cells were then incubated with 2.5µM CFSE in PBS for 10
min at 37°C. CFSE-labeled mononuclear cells (1x106) were administered i.v. into
recipient mice 24 h after the induction of hindlimb ischemia; this cell dose is the
minimum number that consistently stimulated angiogenesis in the hindlimb ischemia
model.

Flow cytometry. The adductor muscle from ischemic and nonischemic hindlimbs was
surgically isolated after hindlimb ischemia and then treated with 3 mg/ml Type I
collagenase (Worthington Biomedical Corp., Lakewood, NJ, USA) for 40 min at
37°C. After filtering through a 50-µm cell strainer (Partec, Munster, Germany), cells
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were incubated with Fc block (Miltenyi Biotec, Auburn, CA, USA) for 10 min at 4°C,
followed by incubation with PE-conjugated antibodies to Gr-1, F4/80, CD3, B220, or
NK1.1 (PharMingen, San Diego, CA, USA). Cells were analyzed on a FACScan flow
cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). Data are reported as the
total number of the indicated cell type recovered from an entire adductor muscle.

Unbiased screen for soluble factors. Following digestion of adductor muscle with
collagenase to generate a single-cell suspension, cells and debris were removed by
centrifugation at 500 x g for 5 min. The cell-free tissue supernatant was recovered and
analyzed using a multiplexed ELISA assay for 58 unique soluble factors (Rules Based
Medicine, Austin, TX, USA).

Statistical analysis. Statistical significance was determined by a two-way ANOVA
analysis or by a two-sided Student’s t-test.

2.4 RESULTS

2.4.1 Monocytes are recruited to ischemic tissue post-HLI. In order to determine
if adoptively transferred monocytes home to the ischemic lesion, donor BM-MNCs
were labeled with CFSE and were injected intravenously into ischemic recipients at
24 hours post-HLI. The ischemic adductor muscle was harvested at several time
points post-ischemia, homogenized, and cell populations contained in this fraction
were analyzed by flow cytometry. As shown in Figure 2.1A, adoptively transferred
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monocytes to home to ischemic tissue, with a peak influx of 2.5x104 cells observed at
24 hours post-adoptive transfer. Likewise, contaminating neutrophils present in BMMNC preparations were observed to home to the ischemic adductor muscle (Figure
2.1B). Interestingly, the adoptive transfer of BM-MNCs lead to increased recruitment
of CFSE- endogenous monocytes to the ischemic adductor muscle with peak numbers
observed at 24 hours post-adoptive transfer (Figure 2.1.C). These data indicate that
both monocytes and neutrophils contained within the adoptively transferred BMMNC fraction home to the site of ischemia, and that a specific recruitment of
additional endogenous monocytes is observed.

2.4.2 An adoptive transfer of the inflammatory, but not resident, subset of
monocytes significantly improves revascularization post-HLI. The recent
designation of the inflammatory and resident subsets of monocytes is based on the
ability of these subsets to traffick in response to thioglycollate. The contribution of
these particular subsets in responding to alternative signals, such as ischemia, has not
been previously examined. In order to determine if the inflammatory and resident
monocyte subsets differ in their ability to promote post-ischemic angiogenesis, we
sort-purified these populations and adoptively transferred them into ischemic
recipients. Revascularization of ischemic recipients was assessed over a 14-day time
course using laser Doppler imaging. While an adoptive transfer of resident
monocytes showed no improvement over PBS-treated controls, an adoptive transfer
of inflammatory monocytes lead to a significant acceleration of revascularization
(Figure 2.2). This finding indicates that the CX3CR1loGr-1+ inflammatory subset is
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uniquely responsible for the enhanced revascularization observed upon an adoptive
transfer of unfractionated monocytes.

2.4.3 The inflammatory subset of monocytes is selectively mobilized from the
bone marrow into the blood post-HLI. Having determined that an adoptive transfer
of inflammatory monocytes significantly increases revascularization post-HLI, we
next assessed the contribution of inflammatory and resident monocyte subsets to the
endogenous response to ischemia. At baseline, the resident monocyte subset
dominates in the peripheral blood while, the inflammatory subset comprises the
majority of bone marrow monocytes. However, in response to hindlimb ischemia, an
increase in the number of inflammatory cells in the blood is observed (Figure 2.3A)
concomitant with an increase in the production of this subset in the bone marrow
(Figure 2.3B). These data indicate that the inflammatory subset of monocytes is
selectively mobilized from the bone marrow into the peripheral blood in response to
hindlimb ischemia.

2.4.4 Monocytes of the inflammatory subset accumulate at the ischemic lesion
post-HLI. As monocytes of the inflammatory subset preferentially mobilize from the
bone marrow to the blood in response to hindlimb ischemia, we next asked if this
subset likewise accumulates at the ischemic lesion. In fact, the monocytic infiltrate in
the ischemic adductor muscle was largely comprised of the inflammatory subset.
Around 106 inflammatory monocytes were observed at the peak time of influx,
whereas levels of resident monocytes peaked at only around 105 cells (Figure 2.4).
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This data suggests that inflammatory monocytes are the major subset mediating repair
at the site of ischemia in this model. This finding contrasts with chronic models of
ischemia in which a bimodal “switch” from inflammatory to resident monocyte
infiltrate is observed (Nahrendorf, 2007; Arnold, 2007).

2.4.5 Bone marrow resident monocytes decrease expression of CX3CR1 upon
induction of ischemia and CX3CR1-/- monocytes exhibit a reduced ability to
improve angiogenesis. In order to understand why the trafficking of a small number
of adoptively-transferred donor monocytes, representing only 0.1-1% of the total
monocytes present in the ischemic lesion, so potently accelerates revascularization we
set out to assess phenotypic differences between donor monocytes and endogenous
monocytes. Interestingly, we observed that upon induction of ischemia, expression of
the fractalkine receptor CX3CR1 is markedly reduced (Figure 2.5A). As CX3CR1 is
known to play a role in adhesion of monocytes to endothelium and also in stimulating
endothelium to produce a variety of angiogenic factors, we set out to assess if the
downregulation of CX3CR1 which occurs as monocytes leave the bone marrow
impairs the downstream angiogenic capacity of these cells. To test this, we sortpurified monocytes from a CX3CR1-/- donor and adoptively transferred these cells
into ischemic recipients. In fact, these cells did exhibit a slight, but statistically
significant, defect in accelerating revascularization compared to wild type controls
(Figure 2.5B). This finding suggests that the loss of CX3CR1 expression that occurs
as monocytes are mobilized from the bone marrow to the periphery may partially
explain the loss of angiogenic capacity of these cells compared to donor cells which
express high levels of this receptor.
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2.4.6. Local production of VEGF, MCP-1, MMP-9, and apolipoprotein A1 is
increased post-adoptive transfer. As CX3CR1 expression in endogenous
monocytes appears to play only a partial role in mediating the proangiogenic effects
of monocytes, we next performed an unbiased screen to determine what factors are
produced locally which may impact revascularization. An unbiased ELISA-based
screen for 58 unique soluble factors was performed on cell-free muscle supernatants
obtained from the ischemic adductor muscles of mice undergoing HLI only (poor
blood flow recovery) and from mice receiving HLI plus an adoptive transfer of BMMNCs (improved blood flow recovery). The screen indicated that levels of the
proangiogenic factors VEGF (Figure 2.6A), MCP-1 (Figure 2.6B), and MMP-9
(Figure 2.6C) as well as the major protein component of HDL, apolipoprotein A1
(Figure 2.6D) were increased upon adoptive transfer. As VEGF, MCP-1, and MMP-9
have well-described roles in post-ischemic angiogenesis, we decided to examine the
importance of apolipoprotein A1 in mediating the potent pro-angiogenic effect of a
monocytic adoptive transfer.

2.4.7. An adoptive transfer of apolipoprotein A1-deficient monocytes does not
improve revascularization post-HLI. ApoA1 is the major protein component of
HDL known to be largely synthesized by hepatocytes in the liver and then exported
into the circulation where it assembles with the lipid components of HDL (ref). The
ApoA1 lipid complex classically is known to play an important role in reverse
cholesterol transport. Synthesis of ApoA1 by monocytes and its role in post-ischemic
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angiogenesis has not been previously described. In order to determine if production
of ApoA1 by monocytes is necessary for monocytes to mediate their angiogenic
effect, we sort-purified inflammatory monoctyes from ApoA1-/- mice and adoptively
transferred them into ischemic recipients. Interestingly, an adoptive transfer of
monocytes lacking ApoA1 was not sufficient to enhance revascularization compared
to wild type controls (Figure 2.7). This data indicates an essential role for ApoA1 in
the angiogenic repair capacity of monocytes.

2.5 DISCUSSION
BM-MNCs have demonstrated efficacy in the treatment of a variety of
ischemic disorders in both mice and humans. Many of these studies have centered on
the role of progenitor populations present in the BM-MNC fraction and their ability to
differentiate into endothelial cells. However, recent work by our laboratory has
demonstrated that the monocyte fraction contained within BM-MNCs potently
enhances revascularization following hindlimb ischemia (Capoccia, 2006). We
observed that adoptively transferred monocytes home to the site of ischemia and also
recruit additional endogenous monocytes to the lesion (Figure 2.1).
A further examination of monocyte subsets revealed that only the
inflammatory and not the resident subset of monocytes is competent to accelerate
revascularization (Figure 2.2). Additionally, the inflammatory subset of monocytes
likewise is selectively recruited from the bone marrow into the blood upon induction
of ischemia and this is the major subset that accumulates at the ischemic lesion at all
time points post-HLI. In several other models including myocardial infarction
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(Nahrendorf, 2007) as well as a muscle injury model (Arnold, 2007), inflammatory
monocytes dominate the early time points while the resident population comprises the
majority of the infiltrate at late timepoints. Interestingly, Tie2-expressing monocytes
(TEMs), thought to be potently angiogenic in tumor models, are thought to fall within
the resident Gr-1- subset of monocytes (Venneri, 2007). Our finding underscores the
potential differences in tumor versus ischemia-driven angiogenesis. These data
provide the first evidence that the CX3CR1loGr-1+ inflammatory subset is the major
contributor to angiogenic repair in response to acute ischemia.
CX3CR1 is the receptor for the fractalkine ligand CX3CL1 which is
expressed as a transmembrane protein on a mucin-like stalk. Interaction of CX3CR1
with this membrane-bound ligand allows for integrin-independent adhesion. The
membrane-bound form of CX3CL1 can also be cleaved by metalloproteases
generating free CX3CL1 which can then act as a chemoattractant. CX3CR1-/- and
CX3CL1-/- mice both demonstrate a reduction in circulating resident monocytes and
normal numbers of inflammatory monocytes. A recent study has demonstrated that
this is due to the critical Bcl2-dependent survival signals generated by the
CX3CR1/CX3CL1 interaction in the resident monoctyes (Landsman, 2009).
Interestingly, local injections of CX3CL1 lead to improved blood flow recovery in a
rat model of hindlimb ischemia (Ryu, 2008). As CX3CR1 expression was markedly
decreased in bone marrow monocytes post-HLI, but intact in donor monocytes from
mice that did not receive surgery, we examined the possible contribution of this
receptor in mounting the angiogenic response. An adoptive transfer of CX3CR1-/monocytes showed a modest, but significant, decrease in revascularization compared
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to CX3CR1-sufficient controls (Figure 2.5). Further studies will be necessary to
determine if this defect in revascularization is due to a decreased ability of CX3CR1-/cells to home to the ischemic lesion, to attach to damaged endothelium via the
CX3CR1/CX3CL1 interaction, or to survive at the inflammatory site.
As the loss of CX3CR1 only appeared to have a minor effect on the
revascularization potential of monocytes, we looked for other ways in which nonischemic donor monocytes may have such a profound impact on the revascularization
of ischemic recipients. To accomplish this, an unbiased screen for 58 unique soluble
factors was performed on adductor muscle supernatant from mice undergoing HLI
with and without an adoptive transfer. Interestingly, the potently angiogenic factors
VEGF, MCP-1, and MMP-9 were all found to be upregulated post-adoptive transfer.
The role of VEGF in recruiting macrophages which contribute to angiogenesis has
been extensively described. For example a host of experiments using neutralizing
antibodies or soluble receptors demonstrated that VEGF is a major contributor to
post-ischemic as well as tumor angiogenesis (Cursifen, 2004; Frank, 1995; Adamis,
1996). Based upon the critical role of this factor in angiogenesis, the increased
production of VEGF observed upon adoptive transfer likely is a large contributor to
the accelerated angiogenesis observed in our model.
Like VEGF, MCP-1 is likewise a well-known regulator of angiogenesis.
MCP-1 is secreted from monocyte/macrophages, smooth muscle cells, and endothelial
cells within ischemic tissue (Goede, 1999; Lakshminarayanan, 2001). In addition,
MCP-1 has been shown to directly induce VEGFA expression from endothelial cells
(Hong, 2005). The addition of recombinant MCP-1 or its overexpression by gene
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transfer has been shown to significantly enhance revascularization in ischemic tissues
which is associated with increased macrophage recruitment (Ito, 1997; Muhs, 2004;
Schwarz, 2004). MCP-1–/– mice had impaired monocyte recruitment and blood flow
recovery after hindlimb ischemia, which could be reversed by local treatment with
purified MCP-1 protein (Vosukil, 2004).
MMP-9 belongs to a family of zinc-containing endopeptidases which play a
role in vascular remodeling by degrading the extracellular matrix (Heissig, 2003).
MMP-9 has been shown to mobilize endothelial progenitor cells (EPCs) from the
bone marrow niche (Hessig, 2002) and to recruit bone marrow-derived leukocytes to
tumors (Jodele, 2005). Secretion of MMP-9 by tumor associated macrophages
(TAMs) is a major signal governing tumor angiogenesis in several models (Coussens,
2004; Giraudo, 2004; Dirkx, 2006). The increased levels of MMP-9 observed postadoptive transfer demonstrate that in addition to its importance in tumor models, this
proteinase likewise plays a critical role in repairing post-ischemic injury.
Apolipoprotein A1 (ApoA1) is the major protein component of the high
density lipoprotein (HDL) complex. While largely described as an anti-inflammatory
regulator, recent evidence suggests that ApoA1 may exhibit anti-inflammatory
functions at the steady state but pro-inflammatory functions under conditions of
systemic inflammation (Navab, 2005). In our model of hindlimb ischemia, ApoA1 is
clearly protective as markedly increased levels are observed post-adoptive transfer
and an adoptive transfer of ApoA1-/- monocytes does not improve revascularization.
Interestingly, ApoA1 is known to be secreted by hepatocytes and some cells of the
small intestine, and its production by macrophages has not been previously described.
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Further studies will be required to determine if monocyte/macrophages do, in fact,
secrete ApoA1, or if alternatively, macrophage development in an ApoA1-deficient
setting leads to phenotypic changes which limits their pro-angiogenic capacity.
Taken together, these data identify a specific subset of monocytes which
potently enhances angiogenesis in an adoptive transfer setting and describe several
factors which are significantly increased in association with this adoptive transfer.
Future studies will be required to delineate the specific mechanism by which an
adoptive transfer of a small proportion of monocytes leads to significantly increased
blood flow recovery. A better understanding of this process may unveil promising
therapeutic strategies for a variety of ischemic disorders.
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Figure 2.1

Adoptively transferred donor monocytes home to the site of ischemia and a
concomitant recruitment of additional endogenous monocytes is observed. Ficollpurified BM-MNCs were harvested from nonischemic donor mice, labeled with
CFSE, and 2x106 cells were adoptively transferred into ischemic recipients at 24
hours post-HLI. The ischemic adductor muscle was harvested at the times indicated,
subjected to collagenase digestion and homogenization, and analyzed by flow
cytometry. The absolute number of CFSE+F4/80+ donor monocytes (A), CFSEF4/80+ endogenous monocytes (B), CFSE+Gr-1hi donor neutrophils (C), and CFSEGr-1hi endogenous neutrophils (D) was determined by multiplying the percentages of
cells obtained by flow cytometry by hemacytometer counts of whole adductor
muscle.

Figure 2.2

An adoptive transfer of the inflammatory, but not resident, subset of monocytes
significantly improves revascularization post-HLI. Monocytes of the CX3CR1loGr-1+
inflammatory and CX3CR1hiGr-1- resident subsets were sort-purified from
CX3CR1+/GFP mice. 2x105 sorted monocytes were adoptively transferred via a tail
vein injection into ischemic recipients at 24 hours post-HLI. The blood flow ratio of
the ischemic versus nonischemic leg was assessed using laser Doppler imaging over a
14 day time course.
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Figure 2.3.

The inflammatory subset of monocytes is selectively mobilized from the bone marrow
into the blood post-HLI. Hindlimb ischemia surgeries were performed in CX3CR1
GFP/+

mice and peripheral blood (A) and bone marrow (B) were harvested at the times

indicated. Percentages of the inflammatory (GFPloGr-1+) or resident (GFPhiGr-1-)
subsets were identified by flow cytometry and multiplied by the total white blood
count in order to determine the absolute number of monocytes present.

Figure 2.4

Monocytes of the inflammatory subset accumulate at the ischemic lesion post-HLI.
CX3CR1GFP/+ mice were subjected to hindlimb ischemia and the ischemic adductor
muscles were harvested at the indicated time points. Muscles were homogenized and
the total number of inflammatory (GFPloGr-1+) and resident (GFPloGr-1-) monocytes
were quantified using percentages obtained using flow cytometry multiplied by
absolute cell numbers obtained by hemacytometer counts (n=3-5).
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Figure 2.5

Expression of CX3CR1 is decreased upon induction of ischemia and CX3CR1-/monocytes demonstrate a reduced capacity to stimulate angiogenesis. (A) Whole
bone marrow was prepared from CX3CR1+/GFP mice at baseline or at 24 hours postHLI. Cells were stained for Gr-1 and analyzed using flow cytometry. (B) The
CX3CR1loGr-1+ inflammatory monocyte subset was sort purified from the bone
marrow of a CX3CR1-/- donor and 2x105 cells were adoptively transferred into
ischemic recipients at 24 hours post-HLI. Mice were analyzed using laser Doppler
scanning over a 14-day time course.

Figure 2.6.

Local production of VEGF, MCP-1, MMP-9, and apolipoprotein A1 is increased
post-adoptive transfer. Ischemic adductor muscles from ischemic mice with (dashed
bars) or without (solid bars) an adoptive transfer of 2x106 BM-MNCs were
harvested. Muscles were treated with collagenase and homogenized as described in
Methods and the cell free supernatant was obtained. Cell free muscle supernatants
were subjected to a multiplex ELISA-based screen for 58 unique soluble factors.
Levels of VEGF (A), MCP-1 (B), MMP-9 (C) and apolipoprotein A1 (D) were
upregulated locally in mice receiving adoptive transfer. (n=1-2 pooled samples,
representing 3-6 mice, respectively).

48

Figure 2.7

An adoptive transfer of apolipoprotein A1-deficient monocytes does not improve
revascularization post-HLI The inflammatory subset of monocytes was sorted from
ApoA1-/- mice based on CD115+Gr-1+ expression. 2x105 of these sorted cells were
adoptively transferred into ischemic recipients at 24 hours post-HLI. The blood flow
ratio of the ischemic versus nonischemic leg was assessed over a 14 day time course
using laser Doppler imaging.
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Chapter 3

Systemic Signals Generated by Interleukin-6 (IL-6) and
Granulocyte-Colony Stimulating Factor (G-CSF)
Influence the Angiogenic Capacity of Bone Marrow
Resident Monocytes
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Gregory, A.D., Capoccia, B. J., Link, D.C. Systemic Signals Generated by IL-6 and
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3.1 ABSTRACT
There is considerable interest in the potential of cell-based approaches to mediate
therapeutic angiogenesis for acute and chronic vascular syndromes. Using a mouse
model of hindlimb ischemia, we previously showed that adoptive transfer of a small
number of donor monocytes significantly enhanced revascularization. Herein, we
provide data suggesting the bone marrow resident monocytes sense systemic signals
that influence their future functional capacity. Specifically, following induction of
distant ischemia, the angiogenic capacity of bone marrow resident monocytes is
markedly reduced. We provide evidence that granulocyte-colony stimulating factor
(G-CSF) and interleukin-6 (IL-6) represent such “conditioning” signals. Systemic
levels of G-CSF and IL-6 are significantly increased following induction of hindlimb
ischemia. Accordingly, bone marrow resident monocytes from ischemic mice
exhibited increased STAT3 phosphorylation and STAT3 target gene expression.
Finally, G-CSF receptor-/- and IL-6-/- mice were resistant to the deleterious effects of
ischemic conditioning on monocyte angiogenic potential. RNA expression profiling
suggested that ischemia-conditioned monocytes in the bone marrow are polarized
towards expression of M2-associated genes. Consistent with this observation, M2skewed monocytes from SHIP-/- mice also had impaired angiogenic capacity.
Collectively, these data show that G-CSF and IL-6 provide signals that determine the
angiogenic potential of bone marrow resident monocytes.
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3.2 INTRODUCTION
The bone marrow represents a rich reservoir of cells that are able to stimulate
angiogenesis. Delivery of bone marrow cells to sites of ischemia, either by direct
injection into ischemic tissue (1) or by mobilization of bone marrow cells into the
blood (2), has been shown to stimulate angiogenesis in animal models. Moreover,
several clinical trials have utilized direct injection of bone marrow cells to stimulate
revascularization. Though preliminary, there is evidence that this approach may have
modest clinical benefit in patients with acute myocardial infarction (3) or peripheral
vascular disease (4). Importantly, the bone marrow is comprised of many cell types,
and the cell population(s) that stimulate angiogenesis have not been fully defined.
The identification of the relevant cell populations and a better understanding of the
signals that regulate their angiogenic activity may lead to improved strategies for cellbased therapeutic angiogenesis.
Within the bone marrow, cell populations with known angiogenic activity
include monocytes, endothelial cells and natural killer cells (5). Accumulating
evidence suggests that monocytes may be the key bone marrow cell type mediating
angiogenesis upon delivery to sites of ischemia. Mice subjected to ischemia exhibit a
marked endogenous monocytic response, consisting of increased production in the
bone marrow and trafficking to the lesion (6). Monocytes are thought to stimulate
angiogenesis through secretion of angiogenic growth factors, degradation of
extracellular matrix by the release of proteases, and increases in vascular permeability
by the deposition of fibrin. Accordingly, ablation of macrophages is associated with
a significant reduction in post-ischemic angiogenesis (7-9). Conversely, we recently
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showed that early delivery of bone marrow monocytes to sites of ischemia markedly
enhanced reperfusion in a murine model of acute hindlimb ischemia (6).
The cytokines granulocyte-colony stimulating factor (G-CSF) and interleukin6 (IL-6) are known to provide important survival and activation signals to
monocyte/macrophages, acting through signal transducer and activator of
transcription 3 (STAT3) signaling intermediates (10). IL-6 and G-CSF are induced in
several ischemic settings including a murine model of ischemic acute kidney injury
(11) and a rat model of gut ischemia/reperfusion (12). Likewise, levels of these
cytokines have been shown to be elevated in a variety of ischemic disorders in
patients, including severe heart failure patients (13, 14) and vascular surgeryassociated ischemia (15). The effect of these cytokines on the bone marrow
compartment has not previously been investigated.
Herein, we demonstrate that the addition of only a small proportion of
adoptively transferred monocytes from a non-ischemic donor significantly enhances
revascularization post-hindlimb ischemia (HLI). Based on this finding we set out to
assess differences in proangiogenic capacity between endogenous ischemiaconditioned monocytes and donor basal monocytes. We demonstrate that ischemiaconditioned monocytes are unable to enhance revascularization post-HLI and that this
defect is dependent upon signaling by G-CSF and IL-6. Additionally, bone marrow
resident monocytes subjected to ischemic signals exhibit reduced expression of
classical M1 genes and increased expression of M2 genes. Accordingly, an adoptive
transfer of M2-skewed monocytes obtained from Src homology 2 domain-containing
inositol 5'-phosphatase 1-/- (SHIP-/-) mice does not improve blood flow recovery
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post-HLI. This study provides the first evidence that systemic signals generated by
ischemia can lead to functional alterations in bone marrow resident monocytes and
has important implications for cell-based therapeutic angiogenesis approaches.

3.3 MATERIALS AND METHODS

Mice. IL-6-/- on a C57BL/6 background were obtained from The Jackson Laboratory
(Bar Harbor, ME). CX3CR1GFP/+ mice on a C57BL/6 background were a generous
gift from Dr. Dan Littman (Skirball Institute of Biomolecular Medicine, New York
School of Medicine, New York, NY). SHIP-/- mice on a C57BL/6 background were a
generous gift from Dr. F. Patrick Ross (Washington University School of Medicine,
St. Louis, MO) G-CSFR-/- mice on a C57BL/6 background were generated as
previously described (43). Mice were housed in a specific pathogen-free
environment. The Washington University Animal Studies Committee (St. Louis,
MO) approved all experiments.

Murine hindlimb ischemia model. Mice were anesthetized by an intraperitoneal
injection of a solution of 87 mg/kg ketamine; 13 mg/kg xylazine. An incision was
made at the mid-portion of the right hindlimb proximal to the femoral artery and the
femoral artery and vein were dissected free from the nerve. The proximal portion of
the femoral artery and vein were ligated with Perma-Hand taper point (6-0)
nonabsorbable silk surgical sutures (Ethicon, Summerville, NJ). The distal portion of
the saphenous artery and vein and remaining arterial and venous side branches were
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ligated and then excised from the hindlimb. The incision was then closed using
Nexaband veterinary glue (Abbott Animal Health, Abbott Park, IL).

Laser Doppler perfusion imaging. Blood perfusion in the hindlimb was monitored
by laser Doppler imaging (MoorLDI-2, Moor Instruments, UK). Prior to imaging,
mice were anesthetized with ketamine/xylazine, and placed on a heating plate at 37oC
for 10 minutes in order to minimize temperature variations. The laser Doppler image
was analyzed by averaging the perfusion, expressed as the relative unit of flux as
determined by Moor Instruments, over the surface of the ischemic and non-ischemic
foot. To control for ambient light and temperature, calculated perfusion was
expressed as the flux ratio between the ischemic and non-ischemic limbs.

Isolation and adoptive transfer of bone marrow mononuclear cells (BM-MNCs)
or purified monocytes. Bone marrow was harvested from the femurs of donor mice
and mononuclear cells were isolated by centrifugation across a 1.011 density gradient
(Histopaque, Sigma-Aldrich, St. Louis, MO) at 1700xg for 30 minutes. Pure
monocyte populations were obtained from CX3CR1GFP/+ mice using a MoFlo high
speed cell sorter (Dako, Fort Collins, CO) based on CX3CR1loGr-1+ expression or
CD115+Gr-1+ expression in mice which do not express CX3CR1-GFP. 2x106 BMMNCs or 2x105 purified monocytes were administered intravenously into recipient
mice 24 hours after the induction of hindlimb ischemia. For trafficking experiments,
cells were incubated with 2.5uM carboxyfluorescein succinimidyl ester (CFSE)
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(Invitrogen, Eugene, OR) in PBS for 10 minutes at 37oC prior to intravenous
injection.

Homogenization of muscle tissue. The adductor muscle was dissected free of the
ischemic hindlimb, subjected to mechanical disruption, and incubated 3 mg/mL
collagenase type I (Worthington Biochemical, Lakewood, NJ) for one hour on a 37°
shaking incubator. Cells were further homogenized by drawing through a 18-gauge
and 22-gauge needle and then filtered through a 50 uM cell filter (Partec, Mt. Laurel,
NJ). The resulting suspension was spun at 8000xg for 5 minutes, and the cell-free
supernatant analyzed by ELISA.

Histological analyses. Ischemic adductor muscles were excised and fixed overnight
in 10% formalin. Tissue was then paraffin-embedded, sectioned, and stained with
hematoxylin/eosin (H&E). The number of newly regenerated myofibrils containing
centrally-localized nuclei was scored by counting 100 cells in three distinct fields of
each section (300 total myofibrils scored). Leukocyte infiltration present in the entire
section area was given a histological score as follows: 1=0-25% affected area; 2=2550% affected area; 3=50-75% affected area; 4=75-100% affected area; n=3, p<0.05.
All scoring was conducted in a blinded fashion by two independent investigators.

Unbiased screen for secreted factors. Cell free supernatants were obtained from
homogenized adductor muscle as described above. Supernatants were analyzed using
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the RodentMap v2.0 multiplex analysis for 58 unique soluble factors (Rules Based
Medicine, Austin, TX).

ELISA. ELISA analysis for G-CSF and IL-6 (R&D Systems, Minneapolis, MN)
were performed according to manufacturer’s instructions.

Flow cytometry. Cells were incubated with the indicated primary antibody for 1
hour at 4°C in PBS containing 0.2% BSA and 0.1% sodium azide. The following
primary antibodies were used: Gr-1, B220, CD3, F4/80, CD115 (eBioscience, San
Diego, CA). Cells were analyzed on a FACScan flow cytometer (BD Bioscience, San
Jose, CA).

Flow cytometric phosphorylation assay. Femurs obtained from ischemic or nonischemic CX3CR1GFP/+ transgenic mice were flushed with PBS containing 0.2%
bovine serum albumin (BSA). Cells were immediately fixed and permeabilized using
BD Cytofix/Cytoperm reagent according to manufacturer’s instructions (BD
Biosciences, San Jose, CA). Permeabilized cells were stained using BD Phosflow
anti-STAT3 or anti-STAT5 antibodies (BD Biosciences). Cells were then gated on
the CX3CR1lo inflammatory monocyte population and the mean fluorescent intensity
measured.

Microarray analysis. CX3CR1-GFPloGr-1+ inflammatory monocytes were sorted
from the bone marrow of CX3CR1GFP/+ transgenic mice, with our without hindlimb
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ischemia, directly into Trizol (Invitrogen, Carlsbad, CA). Three independent
replicates were performed. Total RNA was prepared according to manufacturer’s
instructions, amplified, labeled, and hybridized to a MouseRef-6 BeadChip (Illumina,
San Diego, CA, USA). Expression profiles from basal inflammatory monocytes were
compared to those of ischemia-conditioned monocytes using the Spotfire analysis
program (TIBCO, Somerville, MA, USA). After normalization, mean signal
intensities for each probeset were calculated across the three experiments. Probesets
upregulated or downregulated in ischemia-conditioned monocytes versus basal
monocytes were selected based upon the following selection criteria: (i) mean signal
intensity > 40 in at least two of three probesets corresponding to the upregulated
condition; (ii) greater than threefold changes in mean signal intensity (hereafter
referred to as “fold-induction ratio”). (iii) Statistical significance (P < 0.03) by ttest/Anova. In cases where multiple probesets corresponded to the same gene, the
probeset with the highest average signal intensity and greatest number of present calls
was used.

Statistics. Statistical significance between curves in time courses was determined by
two-way ANOVA with Bonferroni post-testing. Unpaired students’ t-test was
performed on single observation data. Significance was determined as p<0.05.

3.4 RESULTS

69

3.4.1 Adoptive transfer of bone marrow monocytes significantly improves
revascularization in mice after induction of hindlimb ischemia
Monocytes were sort-purified from the bone marrow of donor mice, labeled
with carboxyfluorescein succinimidyl ester (CFSE), and adoptively transferred into
recipient mice 24 hours after surgical induction of unilateral hindlimb ischemia.
Consistent with a previous report by our laboratory (6), infusion of as few as 2 x 105
bone marrow monocytes significantly enhances blood flow recovery as assessed by
laser Doppler analysis (Figure 1A). The number of donor (CSFE+) and recipient
(CSFE-) monocytes recruited to the ischemic adductor muscle was assessed by flow
cytometry (Figure 1B-C). Interestingly, though donor monocytes clearly home to and
are retained in the ischemic tissue, they make up only a small fraction (0.1% to 1%)
of the total monocytes/macrophages present in the lesion. Moreover, in control mice
not receiving donor monocytes, blood flow recovery was significantly delayed
despite the recruitment of a large number of CFSE- host monocytes (Figure 1B-C).
Together, these data suggest dramatic differences in the ability of donor versus host
monocytes to stimulate revascularization.

3.4.2 Adoptive transfer of BM-MNCs from ischemic donors does not improve
revascularization after induction of hindlimb ischemia
Local ischemia/inflammation can induce systemic production of cytokines,
such as IL-6, G-CSF, tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFNγ), and transforming growth factor-beta (TGF-β), that regulate immune cell function
(16). We hypothesized that systemic factors induced by hindlimb ischemia may alter
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the ability of bone marrow resident monocytes to stimulate angiogenesis. To test this
hypothesis, we harvested BM-MNCs from mice 24 hours after induction of hindlimb
ischemia. Of note, cells were obtained only from the non-ischemic hindlimb of the
ischemic donor, as cells present in the femur of the ischemic hindlimb are subject to
local effects of hypoxia and inflammation (Figure 2A). In this study, we refer to
these cells as ischemia-conditioned BM-MNCs and cells from non-ischemic mice as
basal BM-MNCs. Basal or ischemia-conditioned BM-MNCs were adoptively
transferred into recipient mice 24 hours after induction of hindlimb ischemia and
revascularization assessed by laser Doppler imaging (Figure 2B). In contrast to basal
cells, ischemia-conditioned BM-MNCs did not improve blood flow recovery (Figure
2B).
Accelerated restoration of blood flow should result in improved tissue
preservation. To assess the integrity of muscle tissue post-ischemia, we examined
histological sections of ischemic adductor muscle 21 days after induction of HLI
(Figure C-E). Adoptive transfer of basal bone marrow cells resulted in a significant
increase in myofibrils with centrally-located nuclei (Figure 2D), a feature associated
with regenerating myofibrils (17). In contrast, muscle sections obtained from mice
receiving ischemia-conditioned BM-MNCs had reduced myofiber regeneration, as
measured by this assay (Figure 2D). Interestingly, however, an adoptive transfer of
either basal or ischemia-conditioned BM-MNC significantly reduced leukocyte
infiltration present in the ischemic lesion (Figure 2E). Collectively, these data
suggest that the tissue reparative capacity of ischemia-conditioned BM-MNCs is
reduced compared with basal BM-MNCs.
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3.4.3 Ischemia conditioned bone marrow monocytes demonstrate a reduced
capacity to stimulate revascularization
The inability of ischemia-conditioned bone marrow cells to improve blood
flow recovery may be due directly to a reduction in their ability to stimulate
angiogenesis or may be secondary to the loss of angiogenic cells from the bone
marrow. We have previously used sort-fractionation experiments to show that
monocytes of the CX3CR1loGr-1+ inflammatory subset represent the angiogenic cell
type within the BM-MNC fraction (6). In order to assess if this pro-angiogenic
population is, in fact, reduced, we quantified the number of inflammatory monocytes
in the bone marrow 24 hours after induction of ischemia in the contralateral limb.
Compared with baseline bone marrow, no differences in the percentage or absolute
number of inflammatory monocytes in the ischemia-conditioned bone marrow were
observed (Figure 3A & B). We next asked whether ischemic conditioning leads to a
defect in monocyte-promoted angiogenesis on a per cell basis. Inflammatory
monocytes were sorted from the bone marrow of mice at baseline or at 24 hours after
induction of hindlimb ischemia and adoptively transferred into ischemic recipients.
Consistent with our previous data, adoptive transfer of basal inflammatory monocytes
was associated with significant improvement in blood flow recovery (Figure 3C). In
contrast, adoptive transfer of ischemia-conditioned inflammatory monocytes had no
effect on blood flow recovery (Figure 3C). These data suggest that ischemiaconditioned bone marrow resident monocytes have reduced capacity to stimulate
revascularization.
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3.4.4 Ischemia-conditioned monocytes home to sites of ischemia normally
We next assessed whether ischemia-conditioned monocytes are competent to
home to sites of ischemia. Basal or ischemia-conditioned bone marrow monocytes
were labeled with CSFE and adoptively transferred into recipient mice 24 hours after
induction of hindlimb ischemia. The magnitude and kinetics of the accumulation of
ischemia-conditioned monocytes in the ischemic muscle was similar to basal
monocytes (Figure 4), suggesting that homing of ischemia-conditioned monocytes
was normal.
In addition, there was no significant difference in the number of recipient (CFSE-)
monocytes, neutrophils, T cells, or B cells that infiltrated the ischemic tissue (data not
shown).

3.4.5 Ischemia-conditioned bone marrow resident monocytes have increased
STAT3 but not STAT5 activation.
To begin to elucidate the molecular mechanisms responsible for the reduced
angiogenic capacity of ischemia-conditioned monocytes, we sorted basal or ischemiaconditioned monocytes from the bone marrow and performed RNA expression
profiling. Data from three independent experiments were pooled; genes that were
consistently upregulated or downregulated in ischemia-conditioned monocytes are
summarized in Supplemental Tables 1 and 2. Since several well known STAT3
target genes were found to be significantly upregulated in ischemia-conditioned
monocytes, including SOCS3, we next assessed STAT3 activation in these cells.
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Bone marrow cells were harvested from mice at baseline or 24 hours after induction
of hindlimb ischemia and STAT3 and STAT5 phosphorylation in monocytes assessed
using a phospho-flow assay in which CX3CR1lo inflammatory monocytes were gated
(Figure 5A) and mean fluorescence intensity of pSTAT3 or pSTAT5 was assessed
(Figure 5B). Compared with basal monocytes, a modest but significant increase in
STAT3 phosphorylation in ischemia-conditioned monocytes was observed (Figure
5C). In contrast, no difference in STAT5 phosphorylation levels was observed
(Figure 5C) suggesting specific induction of the STAT3 pathway post-ischemia.

3.4.6 The impaired angiogenic capacity of ischemia-conditioned monocytes is
dependent on IL-6 and G-CSF signals
Localized ischemia can lead to the production of inflammatory cytokines that
might contribute to STAT3 activation in bone marrow resident monocytes. To
address this possibility, we performed an unbiased screen for 58 biomarkers,
including many cytokines and chemokines, in the serum of mice at baseline or 24
hours after induction of hindlimb ischemia. Interestingly, the only factor which was
significantly elevated from baseline was IL-6 (data not shown). ELISA confirmed
increased IL-6 levels (Figure 6A). We also assayed for G-CSF by ELISA, as G-CSF
likewise activates STAT3 in monocytes (18), and which was not included in the
unbiased screen. Like IL-6, this cytokine was significantly upregulated in the serum
of ischemic mice (Figure 6B).
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We next asked if the signals generated by G-CSF and IL-6 are responsible for
the impaired ability of ischemia-conditioned monocytes to improve revascularization.
To test this possibility, we assessed the angiogenic capacity of monocytes harvested
from the bone marrow of IL-6-/- or G-CSFR-/- mice at baseline or 24 hours after
induction of hindlimb ischemia. Similar to wild type mice, induction of contralateral
ischemia did not alter the number or percentage of monocytes in the bone marrow of
IL-6-/- or G-CSFR-/- mice (data not shown). Remarkably, ischemic conditioning of
IL-6-/- or G-CSFR-/- monocytes had no affect on their ability to promote
revascularization (Figure 6C & D). These data suggest that signaling by G-CSF and
IL-6 in bone marrow monocytes is a key determinant of their ability to stimulate
revascularization.

3.4.7 Ischemia-conditioned monocytes demonstrate a shift towards the
expression of M2 genes and M2-skewed SHIP-/- monocytes do not improve blood
flow recovery
In response to local environmental signals, tissue macrophages may be
polarized into two broad activation states: classical (M1) and alternative (M2).
Classically activated macrophages are induced by proinflammatory signals such as
IFN-γ and have enhanced cytotoxic and anti-microbial activities. In contrast,
alternative activated macrophages are polarized towards tissue repair and
angiogenesis (19). Though this classification has been designated based on tissue
macrophages, we asked whether bone marrow resident monocytes were undergoing
similar polarization following induction of distant ischemia. Specifically, we
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analyzed the RNA profiling data from basal and ischemia conditioned bone marrow
monocytes for expression of a curated list of well-defined M1- or M2-associated
genes (Supplemental Table 3 & 4) (20-22). Expression of the majority of the M1associated genes was similar, with the exception of 3 genes that were significantly
reduced in ischemia-conditioned monocytes (Figure 7A). Conversely, 7 of 32 M2associated genes were increased in ischemia conditioned bone marrow monocytes
(Figure 7B). Thus, the RNA expression pattern is suggestive of at least partial
polarization towards alternative (M2) activation.
Alternative activation of macrophages is classically associated with tissue
reparation and angiogenesis, not the decreased repair that was observed with
ischemia-conditioned (M2-polarized) monocytes. Thus, we assessed the capacity of
monocytes from SHIP-/- mice to stimulate revascularization in the hindlimb ischemia
model; macrophages in SHIP-/- mice are reported to be preferentially polarized
towards M2 activation (23). Bone marrow monocytes of the inflammatory subset
were sort-purified from SHIP-/- mice and adoptively transferred into ischemic
recipients (Figure 7C). Consistent with our results with ischemia-conditioned
monocytes, M2-skewed monocytes from SHIP-/- mice had markedly reduced capacity
to stimulate revascularization in this model.

3.5 DISCUSSION
In this study, we show that bone marrow monocytes harvested from mice with
distant ischemia have reduced capacity to stimulate angiogenesis upon adoptive
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transfer. Interestingly, this finding is consistent with a recent study in which BMMNCs obtained from patients with chronic ischemic cardiomyopathy were defective
in improving angiogenesis post-HLI in nude mice (24). The bone marrow is
recognized as the major site of monocyte production and provides a reservoir of
monocytes that can be mobilized into the blood in response to stress (25). Our data
suggest that bone marrow resident monocytes also may sense systemic signals that
influence their future functional capacity. This “conditioning” of monocytes in the
bone marrow represents another level of regulation of monocyte activation.
We show that in the hindlimb ischemia model, G-CSF and IL-6 provide such
“conditioning” signals to bone marrow resident monocytes. Systemic expression of
G-CSF and IL-6 were significantly increased after induction of hindlimb ischemia,
reaching levels in the serum that are in seen in other inflammatory conditions (26-28).
Consistent with G-CSF and IL-6 signaling, a modest but consistent increase in
STAT3 phosphorylation and induction of several STAT3 target genes was observed
in ischemia-conditioned bone marrow resident monocytes. Finally, we show that GCSF and IL-6 signaling in monocytes is relevant, since ischemia-conditioned IL-6-/or G-CSFR-/- bone marrow monocytes are able to stimulate revascularization.
Interestingly, systemic levels of G-CSF and/or IL-6 are increased in many
inflammatory conditions (29-31), suggesting that these findings may have broad
relevance for monocyte biology.
G-CSF has been shown to improve tissue recovery in animal models of
hindlimb ischemia (2), myocardial infarction (32), focal cerebral ischemia injuries
(33, 34), and renal ischemia-reperfusion (35, 36). Moreover, clinical trials utilizing
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G-CSF to mobilize cells for adoptive transfer have demonstrated efficacy in the
treatment of peripheral arterial disease in humans (4). While at first glance, these
studies would seem at odds with the current findings that G-CSF inhibits the
angiogenic capacity of monocytes, G-CSF also is a potent mobilizer of monocytes,
endothelial progenitors, and other cells with potential angiogenesis-promoting
activity. Thus, the increased delivery of these cells to sites of ischemia/tissue injury
may overcome the negative effect that G-CSF signaling has on the function of
recruited monocytes. On the other hand, trials of stem cell/leukocyte mobilization by
G-CSF after myocardial infarction in humans have been disappointing (37). It is
possible that monocytes mobilized by alternative agents, such as AMD3100, may
have better efficacy.
Macrophages are known to polarize along the classical M1 activation
pathway or conversely to exhibit an M2 alternative activation phenotype, however
emerging data suggest that macrophage activation is quite heterogeneous and that
these classifications may, in fact, be oversimplified. M1 macrophages are generated
in response to infectious or inflammatory stimuli and function to clear intracellular
pathogens and also play a role in tumor resistance. In contrast, M2 macrophages are
elicited in response to IL-4 and IL-13 (M2a subset) or IL-10 (M2c subset) signaling
and exhibit diverse functions including immunity to extracellular parasites, the
evolution of an allergic response, matrix remodeling, and tumor promotion (38). M2
macrophages have been associated with angiogenesis in vitro (39) and in a wide
variety of tumor models (40). The role that the M2 macrophage subset plays in postischemic angiogenesis, however, has not previously been examined.

78

The M1 and M2 classification of macrophage activation is based on data from
tissue macrophages. Thus, its relevance to monocyte activation in blood or bone
marrow is unclear. With this caveat in mind, our RNA profiling data suggest that
ischemia-conditioned bone marrow monocytes are polarized towards a M2
phenotype. Expression of hallmark M2 genes, Arg1 and Ym1, is increased, while a
trend of decreased expression of several M1-asscoicated genes was observed in
ischemia-conditioned bone marrow monocytes (Supplemental Tables 3 & 4). At first
glance, these results may be counter-intuitive, since M2 activation is associated with
enhanced angiogenesis and tissue repair and not the impaired angiogenic capacity that
was observed. However, these results are consistent with our finding that monocytes
obtained from SHIP-/- mice, known to exhibit preferential M2 polarization, also do
not improve blood flow recovery in ischemic recipients. Likewise, two recent studies
have demonstrated that mice deficient in IL-10, a critical determinant of M2c
polarization, have improved blood flow recovery post-HLI compared to wild type
controls due, at least in part, to the increased levels of VEGF and active matrix
metalloproteinases in these mice (41, 42). Though it will require further study, it is
possible that functions associated with classically activated (M1) macrophages,
including secretion of proinflammatory cytokines and degradation of extracellular
matrix, are advantageous early during the course of tissue reparation following acute
ischemic injury.
In summary, our data demonstrate that monocytes derived from an ischemic
donor have a markedly reduced capacity to improve revascularization compared to
non-ischemic controls. We demonstrate that G-CSF and IL-6 are generated upon
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induction of ischemia and that signaling by these cytokines plays an essential role in
altering the phenotype of bone marrow-resident monocytes, including the induction
of STAT3 target genes and increased expression of well-defined M2-associated
genes. These data provide the first evidence that systemic inflammatory signals lead
to significant functional changes in bone marrow-resident monocytes. A specific
delineation of the ways in which inflammation- and ischemia-driven signals impact
the angiogenic capacity of bone marrow-resident monocytes may have important
implications for the treatment of a variety of ischemic disorders.

3.6 FIGURE AND FIGURE LEGENDS
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Figure 1. The addition of a small proportion of macrophages obtained from an
non-ischemic donor significantly improves revascularization post-hindlimb
ischemia. (A) Monocytes were sort-purified from non-ischemic donors, labeled with
CFSE and adoptively transferred into ischemic recipients at 24 hours post-HLI.
Revascularization of recipients was assessed over 14 days using laser Doppler
imaging. (B) F4/80+ macrophages present in homogenized, ischemic adductor
muscle tissue were gated and assessed for CFSE expression as shown in this
representative histogram plot. (C) The ratio of (CFSE+ donor)/(CFSE- endogenous)
F4/80+ macrophages is shown at several time points post-adoptive transfer (n=3 at 4
and 72 hours; n=10 at 48 hours). Data represent mean ± SEM.
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Figure 2. An adoptive transfer of BM-MNCs obtained from an ischemic donor
does not improve revascularization post-HLI. (A) BM-MNCs were obtained from
the non-ischemic limb of a 24-hour post-HLI donor using Ficoll purification and
injected intravenously into an ischemic recipient at 24 hours post-HLI according to
the scheme illustrated. (B) Blood flow recovery in recipient mice was assessed by
laser Doppler imaging over a 14-day time course; n=6. (C) Ischemic adductor
muscles were obtained at 21 days post-HLI and were sectioned and stained with
H&E. Original magnification x 40. (D) The percentage of newly regenerated
myofibrils containing centrally-localized nuclei, indicated in panel (C) with
arrowheads, was scored by counting 300 cells in three distinct fields of each section;
n=3, p<0.05. (E) Leukocyte infiltration present in the entire section area was given a
histological score as follows: 1=0-25% affected area; 2=25-50% affected area; 3=50-
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75% affected area; 4=75-100% affected area; n=3 p<0.05. Data represent the mean ±
SEM.

Figure 3. Ischemia-conditioned monocytes are not competent to mediate
revascularization. (A) Bone marrow cells were obtained from CX3CR1GFP/+ mice at
baseline (upper panel) or at 24 hours post-ischemia (lower panel) and analyzed by
flow cytometry. The percentages of CX3CR1loGr-1+ inflammatory monocytes are
noted. (B) The absolute number of inflammatory bone marrow monocytes was
quantified by multiplying the percentage obtained by flow cytometry by the total
white blood count per femur (n=5). (C) Laser Doppler analysis of mice receiving
2x105 sort-purified inflammatory monocytes from non-ischemic donors (squares,
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dashed line) or ischemia-conditioned donors (circles, solid line). Data represent the
mean ± SEM, p<0.05.

Figure 4. Adoptively transferred ischemia-conditioned monocytes are competent to
home to ischemic tissue. BM-MNCs were harvested from wild type or 24 hour-post
HLI donors, labeled with CFSE, and intravenously adoptively transferred into
ischemic recipients. At the time points indicated, the absolute number of CFSE+
donor macrophages present in the ischemic adductor muscle was quantified using cell
percentages obtained by flow cytometry multiplied by the total cell number obtained
by hemacytometer counts; n=3 at 4 and 48 hours; n=10 at 24 hours. Data represent
the mean ± SEM.
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Figure 5. Increased STAT3 phosphorylation is observed in ischemia-conditioned
bone marrow monocytes. Bone marrow cells were harvested from non-ischemic or
ischemic mice, immediately subjected to fixation/permeabilization, and stained with a
phospho-specific anti-STAT3 or anti-STAT5 antibodies for flow cytometric analysis.
Inflammatory (CX3CR1-GFPlo) monocytes were gated (A) and mean fluorescent
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intensity of pSTAT3 staining was quantitated (B-C). Data are n=3, representative of
four independent experiments. Data represent the mean ± SEM, p<0.05.

Figure 6. IL-6 and G-CSF are produced upon induction of ischemia and loss of
either of these signals is sufficient to restore the ability of ischemic adoptively
transferred monocytes to promote angiogenesis. (A-B) Serum levels of IL-6 (A) and
G-CSF (B) were assessed at the indicated time points post-HLI. Asterisks denote a
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significant change from baseline, n=4-9. (C-D) Bone marrow monocytes were
purified using cell sorting from non-ischemic (solid line) or 24-hour ischemic (dotted
line) wild type, IL-6-/- (C), or G-CSFR-/- (D) donors and 2x105 cells were adoptively
transferred into ischemic recipients at 24 hours post-HLI. Revascularization of
recipients was then assessed for 14 days using laser Doppler imaging. Data represent
the mean ± SEM, p<0.05.

Figure 7. Differential M1/M2 gene expression post-ischemic conditioning, and
reduced revascularization capacity of SHIP-/- M2-skewed monocytes.
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(A-B) CX3CR1loGr-1+ inflammatory bone marrow monocytes were sort-purified
from mice at baseline or at 24 hours post-HLI and RNA expression profiling
performed on three independent replicates. Shown are normalized signals for all
M1-associated genes (A) or M2-associated genes that displayed consistent changes
(increased or decreased) from control cells. (C) CD115+Gr-1+ monocytes were
sorted from SHIP+/+ (squares, solid line), SHIP+/- (triangles, dashed line) and SHIP-/(circles, solid line) mice and adoptively transferred into ischemic recipients at 24
hours post-HLI. Blood flow recovery was assessed by laser Doppler imaging over a
14-day time course. Data represent the mean ± SEM, p<0.05.
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Supplemental Table 1. Genes upregulated in ischemia-conditioned bone marrow monocytes

Gene
Symbol
serum amyloid A 3
Saa3*
interleukin 1 receptor, type II
Il1r2
leucine-rich alpha-2-glycoprotein 1
Lrg1
suppressor of cytokine signaling 3
Socs3*
sterol O-acyltransferase 2
Soat2
glycosylphosphatidylinositol specific phospholipase D1
Gpld1
interferon induced transmembrane protein 1
Ifitm1
chondroitin sulfate proteoglycan 2
Cspg2
potassium channel, subfamily K, member 13
Kcnk13
serine protease inhibitor, Kunitz type 1
Spint1
insulin-like growth factor binding protein 6
Igfbp6
DNA (cytosine-5-)-methyltransferase 3-like
Dnmt3l
ribosomal protein S19
Rps19
guanine nucleotide binding protein, beta 5
Gnb5
spermidine synthase
Srm
a disintegrin and metalloprotease domain 8
Adam8
complement component 1, r subcomponent-like
C1rl
heat shock protein 1
Hspd1
cytidine 5-triphosphate synthase
Ctps
ribonucleotide reductase M2
Rrm2
The average (+ SEM) raw signal of triplicate experiments is shown.
Genes denoted with * indicate STAT3 target genes.
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Baseline
124 + 50
17 + 1
618 + 257
137 + 79
36 + 6
22 + 10
366 + 54
48 + 8
37 + 4
47 + 2
44 + 5
36 + 12
11 + 3
27 + 7
303 + 173
17 + 7
193 + 35
159 + 84
59 + 28
107 + 49

Ischemiaconditioned
7425 + 1183
368 + 82
7712 + 1477
1191 + 315
296 + 54
164 + 11
2334 + 576
290 + 13
217 + 38
269 + 72
240 + 23
174 + 19
52 + 8
125 + 8
1054 + 80
62 + 7
610 + 28
488 + 38
154 + 15
266 + 18

Fold-

t-test/

Change
59.9
20.6
12.5
8.7
8.2
7.2
6.4
6.4
6.0
5.7
5.5
4.8
4.7
4.6
3.5
3.5
3.2
3.1
2.6
2.5

Anova
0.00
0.01
0.01
0.03
0.01
0.00
0.03
0.01
0.01
0.03
0.00
0.00
0.01
0.01
0.03
0.00
0.02
0.02
0.04
0.04

Supplemental Table 2. Genes downregulated in ischemia-conditioned bone marrow monocytes

Gene
Symbol
ureidopropionase, beta
Upb1
solute carrier family 14 (urea transprorter), member 1
Slc14a1
myxovirus (influenza virus) resistance 2
Mx2
reticulon 1
Rtn1
toll-like receptor 11
Tlr11
2-5 oligoadenylate synthetase-like 2
Oasl2
2-5 oligoadenylate synthetase-like 1
Oasl1
interferon regulatory factor 4
Irf4
similar to Ifi204 protein
LOC240921
interferon-induced protein with tetratricopeptide repeats 2
Ifit2
interferon regulatory factor 7
Irf7
PHD finger protein 11
Phf11
angiotensin receptor-like 1
Agtrl1
peptidyl arginine deiminase, type II
Padi2
Otoferlin
Otof
interferon activated gene 203
Ifi203
ubiquitin specific protease 18
Usp18
D site albumin promoter binding protein
Dbp
angiotensin converting enzyme
Ace
keratin complex 2, basic, gene 7
Krt2-7
The average (+ SEM) raw signal of triplicate experiments is shown.
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Baseline
349 + 24
90 + 24
209 + 28
78 + 14
68 + 11
142 + 33
195 + 9
303 + 32
268 + 58
538 + 67
670 + 42
454 + 105
76 + 9
2136 + 227
212 + 26
287 + 42
816 + 147
179 + 28
218 + 21
139 + 16

Ischemiaconditioned
51 + 15
12 + 2
46 + 11
19 + 12
15 + 2
30 + 3
47 + 10
73 + 8
59 + 10
141 + 23
175 + 7
116 + 42
20 + 2
605 + 22
59 + 1
83 + 13
230 + 8
52 + 4
70 + 47
46 + 10

Fold-

t-test/

Change
0.152
0.159
0.217
0.221
0.229
0.231
0.241
0.244
0.244
0.260
0.265
0.277
0.278
0.288
0.288
0.290
0.295
0.304
0.306
0.321

Anova
0.00
0.03
0.01
0.03
0.01
0.03
0.00
0.00
0.02
0.00
0.00
0.04
0.00
0.00
0.00
0.01
0.02
0.01
0.04
0.01

Supplemental Table 3. M1-associated genes
M1 Genes which change* upon induction of ischemia:

Gene

Symbol

Baseline
A

Ischemia
A

Baseline
B

Ischemia
B

Baseline
C

Ischemia
C

Fold ∆

p-value

chemokine (C-X-C motif) ligand 9; MIG

Cxcl9

133

62

197

47

107

47

0.38

0.03

chemokine (C-C motif) ligand 3; Mip1alpha

Ccl3

1111

395

984

711

106

65

0.56

0.40
0.24

chemokine (C-C motif) ligand 4; Mip1beta

Ccl4

522

368

450

332

281

88

0.59

tumor necrosis factor

Tnf

117

77

167

86

74

55

0.64

0.17

toll-like receptor 5

Tlr5

120

81

98

71

98

69

0.70

0.02

toll-like receptor 7

Tlr7

621

344

502

280

535

303

0.56

0.00

Baseline
A

Ischemia
A

Baseline
B

Ischemia
B

Baseline
C

Ischemia
C

M1 Genes unchanged** upon induction of ischemia:
Gene

Symbol

Fold ∆

p-value

chemokine (C-C motif) ligand 5

Ccl5

88

100

56

20

43

38

0.79

0.75

CD80 antigen

Cd80

315

323

302

281

298

310

1.00

1.00

CD86 antigen

Cd86

751

866

796

721

802

883

1.05

0.50

Fc receptor, IgG, low affinity III

Fcgr3

5474

4899

3387

4016

3109

3634

1.08

0.83

Fc receptor, IgG, low affinity Iib

Fcgr2b

3180

2525

1903

1816

2557

2241

0.87

0.45

Fc receptor, IgG, high affinity I

Fcgr1

1837

901

795

801

636

617

0.82

0.46

interleukin 12a

Il12a

43

67

36

33

87

48

1.02

0.77

interleukin 1 beta

Il1b

204

177

67

86

103

302

1.69

0.44

lymphocyte antigen 64

Ly64

69

82

44

37

60

48

0.94

0.90

toll-like receptor 1

Tlr1

61

57

55

56

74

57

0.90

0.28

toll-like receptor 2

Tlr2

4135

3730

2323

2365

2373

3339

1.11

0.80

toll-like receptor 4

Tlr4

313

374

204

365

275

300

1.36

0.10

toll-like receptor 6

Tlr6

518

507

412

485

401

434

1.08

0.50

Baseline
A

Ischemia
A

Baseline
B

Ischemia
B

Baseline
C

Ischemia
C

9

17

12

14

33

21

Fold ∆
N/A

p-value
N/A

M1 genes not expressed***:
Gene

Symbol

chemokine (C-C motif) receptor 7

Ccr7

nitric oxide synthase 2, inducible, macrophage

Nos2

-4

8

8

1

8

4

N/A

N/A

chemokine (C-C motif) ligand 8

Ccl8

10

-2

-5

-2

16

0

N/A

N/A

15

N/A

N/A
N/A

interferon alpha family, gene 1
interferon alpha family, gene B

Ifna1
Ifnab

12

5

-7

-7

7

21

15

-2

-6

4

-7

N/A

interleukin 1 receptor, type I

Il1r1

2

23

22

13

18

25

N/A

N/A

chemokine (C-X-C motif) ligand 10

Cxcl10

27

10

35

-3

27

-5

N/A

N/A

chemokine (C-X-C motif) ligand 11

Cxcl11

5

7

2

4

9

2

N/A

N/A
N/A
N/A

chemokine (C-C motif) ligand 2

Ccl2

43

43

14

11

21

12

N/A

interleukin 6

Il6

1

1

-2

-3

5

-4

N/A

*All genes which were expressed at levels greater than 40 relative expression units and which showed consistent
induction or reduction across all three data sets are reported as "changed."
**Genes which did not show consistent induction or reduction across all three data sets are reported as "unchanged."
***Genes with a relative expression value <40 are reported as "not expressed."
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Supplemental Table 4. M2-associated
genes
M2 Genes which change* upon induction of
ischemia:
Baseline
A

Ischemia
A

Baseline
B

Ischemia
B

Baseline
C

Ischemia
C

Fold ∆

pvalue

-5

490

1

49

1

23

562.00

0.28

Chi3l3

407

803

194

422

164

391

2.00

0.14

Il1r2

17

419

20

211

17

475

21.00

0.01

C-type lectin, superfamily member 9

Clecsf9

425

993

159

542

110

849

34.00

0.03

leucine-rich alpha-2-glycoprotein 1

Lrg1

1080

9427

566

8880

211

4830

13.00

0.01

vascular endothelial growth factor A

Vegfa

48

169

46

77

44

61

2.00

0.17

chitinase 3-like 4

Chi3l4

10308

13183

5603

9085

2169

10190

1.80

0.02

Symbol

Baseline
A

Ischemia
A

Baseline
B

Ischemia
B

Baseline
C

Ischemia
C

Fold ∆

pvalue

Fcer1g

26927

19555

21773

21268

19015

21467

0.94

0.50

Gene

Symbol

arginase 1, liver (Arg1)

Arg1

chitinase 3-like 3 (Chi3l3)
interleukin 1 receptor, type II (Il1r2)

M2 Genes unchanged** upon induction of
ischemia:
Gene
Fc receptor, IgE, high affinity I, gamma
polypeptide
macrophage galactose N-acetylgalactosamine specific lectin 2

Mgl2

1450

942

960

707

351

828

1.25

0.79

mannose receptor, C type 1
platelet-activating factor acetylhydrolase,
isoform 1b

Mrc1

168

213

203

72

415

231

0.73

0.39

Pafah1b1

2328

1877

1570

1782

1606

1701

1.00

0.86

prosaposin

Psap

27140

22879

27001

28059

23643

25701

0.99

0.85

transforming growth factor, beta 1
triggering receptor expressed on myeloid
cells 2

Tgfb1

1207

910

1138

789

134

885

2.69

0.92

Trem2

1146

946

700

766

1063

596

0.83

0.30

arginase type II

Vti1b

1509

1564

3011

4073

3548

3429

1.12

0.75

Baseline
A

Ischemia
A

Baseline
B

Ischemia
B

Baseline
C

Ischemia
C

Fold ∆

pvalue
N/A

M2 genes not expressed***:
Gene
Fc receptor, IgE, low affinity II, alpha
polypeptide

Symbol
Fcer2a

8

-3

-6

-2

8

-5

N/A

chemokine (C-C motif) ligand 22

Ccl22

-3

10

8

14

12

8

N/A

N/A

chemokine (C-C motif) ligand 17

Ccl17

10

5

3

6

19

-1

N/A

N/A

macrophage scavenger receptor 1

Msr1

-4

-1

-1

-2

7

3

N/A

N/A

macrophage scavenger receptor 2

Msr2

11

-2

17

5

27

-2

N/A

N/A

chemokine (C-C motif) ligand 2

Ccl2

43

43

14

11

21

12

N/A

N/A

chemokine (C-C) receptor 2

Ccr2

-6

-1

5

1

9

-2

N/A

N/A

interleukin 13

Il13

18

23

28

26

30

25

N/A

N/A

interleukin 1 receptor antagonist

IL1RA

62

53

24

18

13

16

N/A

N/A

interleukin 10 (Il10)

Il10

-8

-3

-3

-4

6

-1

N/A

N/A
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chemokine (C-C motif) ligand 17

Ccl17

10

5

3

6

19

-1

N/A

N/A

chemokine (C-C motif) ligand 22

Ccl22

-3

10

8

14

12

8

N/A

N/A

chemokine (C-C motif) ligand 24

Ccl24

12

16

5

10

16

3

N/A

N/A

resistin like alpha/Fizz1

Retnla

-6

-4

-1

-3

12

0

N/A

N/A

cadherin 1

Cdh1

6

6

1

6

12

10

N/A

N/A

folate receptor 2 (fetal)

Folr2

-2

-4

-4

-6

9

9

N/A

N/A

CD163 antigen

Cd163

-7

-2

2

-4

9

-2

N/A

N/A

*All genes which were expressed at levels greater than 40 relative expression units and which showed consistent
induction or reduction across all three data sets are reported as
"changed."
**Genes which did not show consistent induction or reduction across all three data sets are reported as "unchanged."
***Genes with a relative expression value <40 are reported as "not expressed."
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Chapter 4

Summary and Future Directions
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4.1 SUMMARY
The studies outlined in this work lend insight into the mechanisms governing
the regulation of angiogenesis by monocytes and also may have important
implications for the design of cellular therapies for angiogenic disorders. In this work
we demonstrated that monocytes of the inflammatory subset are rapidly recruited to
the ischemic tissue post-hindlimb ischemia. A further proof of the importance of
these cells in regulating post-ischemic angiogenesis was the accelerated
revascularization observed when these cells were adoptively transferred into an
ischemic recipient. We also identified several factors that were produced upon
adoptive transfer—VEGF, MCP-1, and MMP—each of which is a known player in
the angiogenic repair. Additionally, we identified apolipoprotein A1, a factor with a
previously unknown role in angiogenesis, to be upregulated post-adoptive transfer.
Interestingly, this protein must play a critical role in the mechanism by which
adoptively transferred cells accelerate revascularization as ApoA1-/- monocytes did
not mediate this effect.
Having established that an adoptive transfer of monocytes does potently affect
revascularization, we next sought to identify the ways in which the ischemic
recipients’ own endogenous monocytes differed functionally from the non-ischemic
donor cells used for the adoptive transfer. We demonstrated that an adoptive transfer
of monocytes obtained from an ischemic donor do not accelerate revascularization in
the hindlimb ischemia model. Our studies revealed that post-hindlimb ischemia there
99

is a marked increase in systemic levels of IL-6 and G-CSF and this is associated with
increased STAT3 phosphorylation in bone marrow-resident monocytes. In addition
to the increased STAT3 activation observed, bone marrow resident monocytes also
exhibited increased expression of M2 genes and a reduction in expression of M1
genes. In keeping with this finding, an adoptive transfer of SHIP-/- monocytes which
are preferentially skewed to the M2 phenotype, does not accelerate revascularization
in the hindlimb ischemia model. This finding runs counter to tumor angiogenesis
studies in which M2 macrophages are major contributors to angiogenesis and
underscores the need to explore macrophage-regulated angiogenesis in a variety of
ischemic settings. Taken together our data identify a potent pro-angiogenic subset of
monocytes (CX3CR1loGr-1+ inflammatory subset) and also reveal a profound defect
in the ability of ischemia-conditioned monocytes to accelerate recovery from
ischemia. These findings can be exploited clinically by modifying current cell-based
therapies for ischemic disorders such that they contain only this pro-angiogenic
monocyte population (and not simply the unfractionated mononuclear cell
compartment) and also potentially to obtain these cells from a matched, nonautologous donor in order to avoid the negative impact of the ischemic-conditioning
observed in our studies.

4.2 APPLICATION TO OTHER ISCHEMIC MODELS
A limitation of the studies described in this work is that only one model of
ischemia and angiogenesis has been explored. The mouse model for hindlimb
ischemia we utilized generates an acute ischemia that is largely resolved after
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approximately three weeks. Therefore it is would be useful to compare the findings
we obtained using this model and compare with other models of acute ischemia such
as myocardial infarction or acute ischemic kidney injury to see if our findings
regarding the efficacy of a monocyte adoptive transfer hold true in these settings as
well. While differences between these models will certainly exist, shared findings
with regard to monocyte subsets involved and factors produced will corroborate and
strengthen our conclusions from the hindlimb ischemia model.
In the majority of patients with critical limb ischemia, atherosclerosis—which
is a chronic, persistent inflammatory state—is the underlying cause. In this way, our
model for hindlimb ischemia does not accurately replicate this disease state. It would
be useful to compare our findings from the acute ischemia model utilized in our
studies to a model for chronic ischemia. For example, a model has been recently
described in which the femoral artery excision surgery is performed in an ApoE-/mouse; the combination of the femoral artery excision with the persistent
inflammatory state in this mouse model better replicates chronic ischemia than
femoral artery excision alone (Kang, 2008). Results obtained from this model would
provide insight into the ways in which the monocytic response differs between an
acute versus a chronic ischemic insult.
In addition to exploring the ways in which treatment with monocytes may be
used as a pro-angiogenic therapy for ischemic disorders, it would also be useful to
explore ways in which our findings may regulate pathologic neovascularization such
as that observed during macular degeneration. It would be useful to extend our
findings to oxygen-induced retinopathy (OIR) and laser-induced choroidal
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neovascularization (CNV) studies which model this disorder. Such studies could
focus on which macrophage subsets accumulate during the course of
neovascularization. It may also be useful to attempt to prevent neovascularization by
neutralizing the pro-angiogenic factors we described in Chapter 2—for example
treating these animals with the apolipoprotein A1 mimetic pepide in an effort to
reduce angiogenesis.

4.3 ROLE OF TYPE I INTERFERON
In addition to revealing that several STAT3 targets were upregulated in
ischemia-conditioned monocytes, microarray data revealed that several type I
interferon-regulated genes were significantly downregulated (Table 3.2). The role of
type I interferons in the response to ischemia has not been extensively examined,
however one study reported that IFNα/β, and not IFN-γ, is specifically induced in a
mouse model of acute liver ischemia (Zhai, 2008). The role that IFNα/β may play in
regulating the development of bone marrow-resident monocytes is unclear. One
recent set of in vitro studies has indicated that bone marrow monocytes cultured
under M2-polarizing conditions produce more endogenous IFN-β and express a far
greater number of type I interferon target genes than do monocytes cultured under
M1-polarizing conditions (Fleetwood, 2009). If this finding hold true in vivo it may
represent an important regulatory mechanism for the downstream polarization of bone
marrow resident monoctyes. Further studies are required in order to determine if
tonic IFNα/β signaling does, in fact, occur in the bone marrow and what specific
implications this regulation has on the downstream phenotype of these cells.
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4.4 CLINICAL TRIAL USING MOBILIZING AGENTS TO RECRUIT
MONOCYTES
Our laboratory is currently enrolling patients with critical limb ischemia for a
clinical trial in which they are treated for 10 days with G-CSF, a potent mobilizing
agent, or placebo. A total of 60 patients will be enrolled with 30 patients each in the
treatment and placebo arms. Eligibility criteria for patient enrollment includes a
diagnosis of critical limb ischemia, defined as the presence of a non-healing ulcer or
rest pain, secondary to peripheral arterial disease (PAD). Patients in this study must
not be candidates for a surgical revascularization procedure. Additionally patients
must have an absolute neutrophil count in the normal range and may not demonstrate
an active infection or malignancy. CD14/CD16 monocyte subsets as well as
endothelial progenitor cells (EPCs) and lymphocytes will be measured by flow
cytometry in peripheral blood obtained from patients prior to treatment as well as at
and day 10 post-treatment. The efficacy of this treatment will be assessed clinically
by measuring ulcer size, ankle-brachial index, toe pressures, as well as a pain
assessment. The primary endpoint for these studies will be the rate of amputation at
one year post-treatment. The results of this study will demonstrate the specificity and
magnitude of recruitment of the CD14-CD16+ and CD14+CD16- human monocyte
subsets in response to treatment with G-CSF. This study will also determine if
mobilization of bone marrow-derived hematopoietic cells represents an efficacious
treatment for critical limb ischemia. If the results of this trial are disappointing, a
modified protocol in which an alternative mobilizing agent, such as AMD-3100 may
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yield better results based on the finding presented in this work that G-CSF, while it
actively recruits monocytes to a site of ischemia, may also reduce their proangiogenic potential.

104

4.5 REFERENCES

1.

Fleetwood, A.J., H. Dinh, A.D. Cook, P.J. Hertzog, and J.A. Hamilton. 2009.
GM-CSF- and M-CSF-dependent macrophage phenotypes display differential
dependence on Type I interferon signaling. J Leukoc Biol.

2.

Kang, J., H. Albadawi, V.I. Patel, T.A. Abbruzzese, J.H. Yoo, W.G. Austen,
Jr., and M.T. Watkins. 2008. Apolipoprotein E-/- mice have delayed skeletal
muscle healing after hind limb ischemia-reperfusion. J Vasc Surg 48:701-708.

3.

Zhai, Y., B. Qiao, F. Gao, X. Shen, A. Vardanian, R.W. Busuttil, and J.W.
Kupiec-Weglinski. 2008. Type I, but not type II, interferon is critical in liver
injury induced after ischemia and reperfusion. Hepatology 47:199-206.

105

